<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hemostatic abnormalities in patients with liver disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hemostatic abnormalities in patients with liver disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hemostatic abnormalities in patients with liver disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicolas Intagliata, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Neeral L Shah, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H61498913"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic discusses the hemostatic abnormalities in patients with liver disease and our approach to common clinical problems, including treatment of bleeding, invasive procedures, and management of venous thromboembolism (VTE).</p><p>Diagnosis and management of portal vein thrombosis, liver injury, cirrhosis, and liver disease from alcohol use are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3579.html" rel="external">"Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/88014.html" rel="external">"Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16729.html" rel="external">"Surgical techniques for managing hepatic injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15143.html" rel="external">"Management of hepatic trauma in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7151.html" rel="external">"Hematologic complications of alcohol use"</a>.)</p><p></p><p class="headingAnchor" id="H61498865"><span class="h1">PHYSIOLOGIC EFFECTS OF HEPATIC DYSFUNCTION</span></p><p class="headingAnchor" id="H2942787953"><span class="h2">Overview of abnormalities</span><span class="headingEndMark"> — </span>Individuals with liver disease have a variety of hemostatic abnormalities, which are generally accepted to result in "rebalanced" hemostasis in which diminished hepatic function leads to both procoagulant and anticoagulant effects [<a href="#rid1">1,2</a>]. These changes increase risks of bleeding as well as thrombosis. They become especially important in patients with bleeding and thrombotic risks such as gastrointestinal varices and vascular stasis, respectively. </p><p>All stages of the hemostatic process may be abnormal, including primary hemostasis (platelet adhesion and activation), coagulation (generation and crosslinking of fibrin), and fibrinolysis (clot dissolution) [<a href="#rid3">3,4</a>]. Clinicians should not presume that patients with severe liver disease and abnormalities of coagulation testing are "auto-anticoagulated." There is overwhelming evidence that standard coagulation testing does not accurately assess bleeding or clotting risk in patients with cirrhosis. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis"</a> and <a class="local">'Prothrombotic changes'</a> below and <a class="local">'Altered fibrinolytic system'</a> below.)</p><p>Factors that contribute to increased risks of both bleeding and thrombosis include altered blood flow, diminished numbers and function of platelets, and inflammatory alterations in endothelial cells [<a href="#rid1">1,5</a>]. These changes may result in a relatively balanced steady state in some patients, but it is generally accepted that susceptibility to both bleeding and thrombosis may be increased, with the relative balance or imbalance different for each patient and clinical circumstance. The risks of bleeding and thrombosis are not reflected in the conventional indices of coagulation status such as the prothrombin time (PT), international normalized ratio (INR), or activated partial thromboplastin time (aPTT). Of interest, elevation of von Willebrand factor (VWF) and the ratio of factor VIII to protein C carry independent prognostic importance in patients with cirrhosis [<a href="#rid6">6</a>]. The historical assumption that individuals with liver disease are "auto-anticoagulated" is now understood to be inaccurate.</p><p class="headingAnchor" id="H61498752"><span class="h2">Impaired hemostasis</span><span class="headingEndMark"> — </span>Patients with liver disease are a heterogeneous population, and multiple abnormalities of hemostatic function may coexist in an individual patient leading to risks of hypo- and/or hypercoagulability. </p><p>Patients with cirrhosis can vary across a spectrum of disease stability ranging from well-compensated cirrhosis to advanced disease with multiorgan failure. For example, patients with acute-on-chronic liver failure (ACLF) may have altered hemostatic function relative to patients with compensated cirrhosis [<a href="#rid7">7-10</a>]. </p><p class="headingAnchor" id="H61501303"><span class="h3">Coagulation factor deficiencies</span><span class="headingEndMark"> — </span>The hepatocyte is the site of production of almost all of the numbered coagulation factors including fibrinogen (factor I), thrombin (factor II), and upstream factors V, VII, IX, X, and XI. Notable exceptions are factor VIII, which is produced in endothelial cells, and the factor XIII A-subunit, which is produced in megakaryocytes [<a href="#rid11">11,12</a>]. In addition to synthesizing coagulation proteins, hepatocytes also make post-translational modifications such as glycosylation and gamma-carboxylation of some factors. Both synthesis and post-translational modification may be impaired in liver disease, affecting coagulation factor abundance and function, respectively. (See  <a class="medical medical_review" href="/d/html/1318.html" rel="external">"Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla"</a>.)</p><p>In some patients with liver disease, particularly those actively using alcohol, <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> deficiency can further exacerbate deficiencies of vitamin K-dependent factors (II [prothrombin], VII, IX, and X) and/or lead to improper modifications (eg, under-gamma carboxylation of prothrombin) [<a href="#rid13">13</a>]. Qualitative defects in factors such as fibrinogen structure may further contribute to coagulopathy in cirrhosis [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H61501309"><span class="h3">Thrombocytopenia and platelet dysfunction</span><span class="headingEndMark"> — </span>Patients with liver disease may have normal platelet counts (ie, ≥150,000/microL) or varying degrees of thrombocytopenia. Mild thrombocytopenia (eg, platelet count between 100,000 and 150,000/microL) has been reported in up to 75 percent of patients with chronic liver disease, and moderate thrombocytopenia (eg, between 50,000 and 100,000/microL) has been reported in approximately 13 percent of individuals with cirrhosis [<a href="#rid15">15,16</a>]. </p><p>Secondary to rebalanced hemostasis in liver disease, there does not appear to be a strong correlation between thrombocytopenia and bleeding risk in these individuals, especially for platelet counts &gt;50,000/microL.</p><p>The mechanism of thrombocytopenia in liver disease may include impaired platelet production, from decreased hepatic synthesis of thrombopoietin; bone marrow suppression, from hepatitis C virus (HCV) infection or alcohol use, other infection, or antiviral or antibiotic therapy; and increased platelet sequestration in the spleen, in the setting of portal hypertension and hypersplenism [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/6673.html" rel="external">"Biology and physiology of thrombopoietin"</a> and  <a class="medical medical_review" href="/d/html/3676.html" rel="external">"Extrahepatic manifestations of hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/d/html/7134.html" rel="external">"Splenomegaly and other splenic disorders in adults", section on 'Hypersplenism'</a>.)</p><p>In addition to thrombocytopenia, individuals with advanced liver disease may have reduced platelet function due to coexisting acute kidney injury, infection, and/or endothelial abnormalities [<a href="#rid17">17</a>]. </p><p>The overall incidence of infection in patients with liver disease has been estimated to be as high as 30 percent [<a href="#rid18">18</a>]. Overt sepsis or low levels of endotoxemia can impair platelet function in patients with cirrhosis. Moreover, infection is associated with increases in endogenous glycosaminoglycans known as heparinoids (eg, heparan sulfate, dermatan sulfate), which can act as anticoagulants; these increases may result from changes in nitric oxide metabolism or other endothelial changes [<a href="#rid19">19,20</a>].</p><p class="headingAnchor" id="H61501315"><span class="h3">Altered fibrinolytic system</span><span class="headingEndMark"> — </span>The fibrinolytic system is altered in patients with cirrhosis and can have significant changes in pro- and antifibrinolytic factors [<a href="#rid7">7,10</a>]. Fibrinolysis (dissolution of the fibrin clot) is often increased in liver disease; however, evidence is emerging that this system can be rebalanced and place patients at risk for both bleeding and thrombosis. </p><p>Laboratory evidence of systemic fibrinolysis can be detected in patients with chronic liver disease. However, clinically evident hyperfibrinolysis is less common and has been estimated to occur in 5 to 10 percent of those with decompensated cirrhosis [<a href="#rid21">21-23</a>]. Hyperfibrinolysis promotes premature clot dissolution and interferes with clot formation due to the consumption of clotting factors.</p><p>Hyperfibrinolysis overlaps with a condition in cirrhosis that resembles disseminated intravascular coagulation (DIC), called "accelerated intravascular coagulation and fibrinolysis (AICF)," but it can be evident as a distinct clinical entity with intractable delayed bleeding from surgical interventions or dental extractions, or on occasion spontaneous bleeding without any recognizable trauma [<a href="#rid24">24</a>]. However, the lack of a commonly available means to clearly identify this condition (such as via the use of viscoelastic tests) often impedes the diagnosis of hyperfibrinolysis in patients with cirrhosis. Even with these global tests of clot formation and dissolution, widely accepted criteria for milder cases of hyperfibrinolysis are not yet established.</p><p>Hypofibrinolysis can occur in decompensated cirrhosis and lead to risks of thrombosis [<a href="#rid25">25</a>]. In a study involving 36 patients with acute-on-chronic liver failure (ACLF), the presence of hypofibrinolysis as diagnosed by viscoelastic testing was associated with a poor prognosis [<a href="#rid8">8</a>].</p><p>Hepatocytes and Kupffer cells are also responsible for clearing coagulation factors and products of fibrinolysis from the circulation [<a href="#rid26">26</a>]. Thus, chronically impaired liver function in cirrhosis may be associated with multiple mechanism(s) of altered fibrinolysis:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased levels of tissue plasminogen activator (tPA), which generates plasmin [<a href="#rid27">27</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased levels of alpha 2 antiplasmin, coagulation factor XIII [<a href="#rid28">28</a>], and thrombin-activatable fibrinolysis inhibitor (TAFI) [<a href="#rid27">27</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated levels of fibrin degradation products such as D-dimer.</p><p class="bulletIndent1"><span class="glyph">●</span>Fibrinolytic activity of ascitic fluid that may be delivered to the systemic circulation via the thoracic duct [<a href="#rid29">29</a>].</p><p></p><p>These processes are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Clot dissolution and fibrinolysis'</a>.)</p><p class="headingAnchor" id="H61498758"><span class="h2">Prothrombotic changes</span><span class="headingEndMark"> — </span>The following changes may be seen:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduced protein S, C, and antithrombin</strong> – In addition to synthesizing clotting factors, the liver also produces endogenous inhibitors of coagulation (eg, protein S, protein C, antithrombin [AT; formerly called AT III]) and fibrinolytic factors. Liver disease may contribute to a prothrombotic state because these natural inhibitors may be reduced [<a href="#rid30">30-33</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased VWF</strong> – Von Willebrand factor (VWF), derived from endothelial cells, is elevated in patients with cirrhosis and may contribute to prothrombotic changes that balance bleeding risks associated with thrombocytopenia [<a href="#rid34">34,35</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased PAI-1</strong> – Liver disease may also be associated with increases in acute phase reactants, such as plasminogen activator inhibitor 1 (PAI-1), and decreased levels of the VWF-cleaving protease ADAMTS13, as well as inflammatory changes in endothelial cells that promote thrombosis [<a href="#rid35">35,36</a>]. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Control mechanisms and termination of clotting'</a> and  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Clot dissolution and fibrinolysis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased D-dimer</strong> – D-dimer may be increased due to altered fibrinolysis and/or decreased hepatic clearance [<a href="#rid32">32</a>]. (See <a class="local">'Altered fibrinolytic system'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduced blood flow</strong> – Reduced vascular flow also contributes to local prothrombotic tendencies. Examples include stasis in the portal circulation and lower extremity venous stasis due to peripheral edema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – Infections such as bacterial peritonitis or a chronic inflammatory state may further exacerbate these changes in endothelial reactivity and/or blood flow [<a href="#rid37">37</a>].</p><p></p><p>While these prothrombotic changes are increasingly appreciated, standard tests of coagulation do not effectively measure them.</p><p class="headingAnchor" id="H61501321"><span class="h2">Significance of type of liver disease</span><span class="headingEndMark"> — </span>Many of the hemostatic abnormalities in liver disease are similar regardless of the underlying cause of liver injury [<a href="#rid38">38</a>]. However, some differences have been reported. As examples [<a href="#rid39">39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cholestatic liver diseases such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) appear to have a less pronounced effect on anticoagulant than procoagulant mechanisms and may be at higher risk for portal vein thrombosis. This mild hypercoagulability may be mediated by changes in platelet activity [<a href="#rid40">40-42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonalcoholic fatty liver disease (NAFLD) may confer a greater prothrombotic risk [<a href="#rid43">43-45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute-on-chronic liver failure (ACLF) and acutely decompensated liver disease may represent a distinct population with unique coagulopathies [<a href="#rid7">7-9,46,47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute liver failure may have a lower incidence of thrombocytopenia but more severe reductions in procoagulant and anticoagulant factors, compared with chronic hepatic insufficiency [<a href="#rid48">48</a>]. Clinically significant bleeding is nonetheless uncommon in patients with acute liver failure [<a href="#rid49">49</a>].</p><p></p><p class="headingAnchor" id="H61498782"><span class="h1">LABORATORY ABNORMALITIES</span></p><p class="headingAnchor" id="H437954833"><span class="h2">Coagulation testing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PT and aPTT</strong> – Individuals with liver disease frequently have abnormalities in routine laboratory tests of coagulation, including prolongations of the prothrombin time (PT), international normalized ratio (INR), and activated partial thromboplastin time (aPTT), along with mild thrombocytopenia, elevated D-dimer, especially when liver synthetic function is more significantly impaired and portal pressures are increased [<a href="#rid5">5</a>]. However, these tests are very poor at predicting the risk of bleeding in individuals with liver disease because they only reflect changes in procoagulant factors [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1">We use the PT/INR as a prognostic measure (eg, in calculating the Model for End-stage Liver Disease [MELD] score) rather than a means of bleeding risk assessment. Prolongation of the INR probably does reflect instability of the overall hemostatic balance, but it does not indicate hypo- or hypercoagulability in cirrhosis. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrinogen</strong> – Plasma levels of fibrinogen can also be used to risk stratify bleeding risk in chronic liver disease patients. At sites of vessel injury, fibrinogen is converted by thrombin into fibrin for clot formation. Fibrinogen levels can be low in chronic liver disease, which may reduce clot formation potential. Measurement of fibrinogen and adequate repletion, if low, could prevent bleeding episodes in cirrhosis patients, and one study of variceal banding patients showed higher rates of bleeding in those patients with low fibrinogen levels, which may have been a reflection of the severity of portal hypertension [<a href="#rid50">50</a>]. However, efforts to replace fibrinogen with Cryoprecipitate do not appear to change bleeding outcomes [<a href="#rid51">51</a>]. Rather, low fibrinogen, similar to thrombocytopenia, may reflect critical illness and advanced liver disease more prone to bleeding or thrombosis. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TEG and ROTEM</strong> – Viscoelastic testing such as thromboelastography (TEG) or thromboelastometry (ROTEM) is increasingly studied in patients with liver disease, but clinical use is mainly confined to perioperative transfusion guidance in patients undergoing liver transplantation [<a href="#rid2">2,11,52-54</a>]. </p><p></p><p class="bulletIndent1">TEG and ROTEM both produce a tracing that reflects dynamic changes in clot formation and lysis, assessed from the changes in torque between a pin and a cup that occur as blood clots; parameters of clot formation time and firmness can be read from the tracing  (<a class="graphic graphic_figure graphicRef100078" href="/d/graphic/100078.html" rel="external">figure 1</a>). In TEG, the cup rotates and the pin is stationary; in ROTEM, the pin rotates and the cup is stationary. Further information about parameters and interpretation of viscoelastic testing is presented separately. (See  <a class="medical medical_review" href="/d/html/15147.html" rel="external">"Etiology and diagnosis of coagulopathy in trauma patients", section on 'Viscoelastic hemostatic assays'</a> and  <a class="medical medical_review" href="/d/html/4433.html" rel="external">"Platelet function testing", section on 'Viscoelastic testing (TEG and ROTEM)'</a>.)</p><p></p><p class="bulletIndent1">In general, studies of TEG and ROTEM in patients with liver disease have shown decreased use of blood products due to the ability of these devices to confirm relatively preserved hemostatic function despite thrombocytopenia and a prolonged INR [<a href="#rid55">55-57</a>]. </p><p></p><p class="bulletIndent1">However, study design limitations in this field have not established baseline bleeding risk in individuals who do not receive bleeding prophylaxis [<a href="#rid58">58</a>]. Therefore, evidence for the value of viscoelastic testing in liver disease remains very limited without clear established parameters, and the sensitivity of these tests to detect subtle coagulation changes is questionable.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective review of TEG parameters in 344 individuals hospitalized with cirrhosis found that most of the patients had preserved clot initiation (R value  (<a class="graphic graphic_figure graphicRef100078" href="/d/graphic/100078.html" rel="external">figure 1</a>)) and propagation (K value and alpha angle), but clot strength (maximum amplitude [MA]) was impaired [<a href="#rid59">59</a>]. Reduced MA was largely attributed to thrombocytopenia. These parameters correlated with disease severity and overall survival but did not provide additional information over and above the model for end-stage liver disease (MELD) score. Another study using TEG found conventional parameters to be abnormal (INR and platelets), whereas TEG parameters were often within normal ranges [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A small study comparing ROTEM parameters in blood samples from 51 patients with cirrhosis found that the parameters most likely to be abnormal in cirrhosis were the clot formation time and the maximum clot firmness; in contrast, the coagulation time was normal in more than one-half of the samples from cirrhotic individuals [<a href="#rid61">61</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective study in patients undergoing liver transplantation found patients with more advanced cirrhosis had hypocoagulable profiles on TEG [<a href="#rid62">62</a>]. There was a correlation between hypocoagulable TEG profile and risk of six-week incidence of variceal bleeding prior to liver transplantation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Additional small studies suggest that viscoelastic testing may be able to predict hypercoagulability in liver disease [<a href="#rid63">63</a>]. </p><p></p><p class="bulletIndent1">We typically do not use viscoelastic testing alone (as the sole basis) to guide decisions regarding transfusions for prophylaxis or rescue interventions. As noted below, we also incorporate information about disease state, comorbidities, and individual clinical judgment in making these decisions. Some recommendations support the use of viscoelastic testing in patients who are critically ill with acute on chronic liver failure [<a href="#rid64">64</a>]. While viscoelastic testing is a promising modality for hemostasis assessment prior to procedures in patients with cirrhosis, other societal guidelines acknowledge the need for further study to better define predictive capabilities and parameters for routine use [<a href="#rid2">2,65</a>]. (See <a class="local">'General approach to managing bleeding'</a> below.)</p><p></p><p class="headingAnchor" id="H1670841013"><span class="h2">Interventions for hemostatic imbalance</span><span class="headingEndMark"> — </span>In most patients, we do not intervene in the setting of asymptomatic laboratory changes (eg, elevations in the PT/INR or aPTT, decreases in the platelet count) that are thought to be due to the underlying liver disease. </p><p>In some cases, we give <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> to patients with suspected vitamin K deficiency. This includes individuals with suspected poor nutrition and cirrhosis, as well as those with cholestatic disease, diarrheal illness, or antibiotic use. The response can be useful in establishing the underlying degree of liver disease-related synthetic dysfunction but has not been shown to alter bleeding or thrombosis risk per se. Dosing is described below. (See <a class="local">'General approach to managing bleeding'</a> below.) </p><p>We do not administer Fresh Frozen Plasma (FFP) to "correct" an asymptomatic prolonged PT/INR, based on a large number of possible risks and costs of this approach (eg, transfusion reactions, volume overload, increased portal pressures) and the lack of good quality evidence that it provides any clinically important benefit [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/7920.html" rel="external">"Clinical use of plasma components", section on 'Risks'</a>.)</p><p>Cases that require further investigation or in which we may intervene include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Large or unexpected changes such as newly prolonged PT or aPTT or new decline in platelet count may require evaluation for the cause, which may include infection, new medication(s), or progression of the underlying liver disease. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Evaluation of abnormal results'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New acute severe thrombocytopenia, which can be associated with medication reaction, disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP) or other thrombotic microangiopathy, or heparin-induced thrombocytopenia (HIT) in patients receiving heparin. In the absence of bleeding or an imminent procedure, such cases warrant close observation and sometimes further investigation, but not platelet administration unless critical such as a platelet count &lt;10,000 to 15,000/microL. (See  <a class="medical medical_review" href="/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults", section on 'Approach to evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Active bleeding may require more aggressive correction of hemostatic abnormalities, although this should be based largely on a thorough clinical assessment rather than isolated laboratory testing such as the PT/INR, which does not provide a full picture of hemostasis in patients with liver disease. Bleeding prophylaxis prior to invasive procedures to prevent future bleeding is controversial, and data are too limited to support prophylactic plasma as a routine practice [<a href="#rid2">2</a>]. (See <a class="local">'Bleeding'</a> below and <a class="local">'Invasive procedures'</a> below.)</p><p></p><p class="headingAnchor" id="H61498800"><span class="h2">Liver disease versus DIC</span><span class="headingEndMark"> — </span>Reduced synthesis of procoagulant and anticoagulant factors predominates in liver disease; the term "accelerated intravascular coagulation and fibrinolysis (AICF)" is used for these. (See <a class="local">'Impaired hemostasis'</a> above.)</p><p>In contrast, disseminated intravascular coagulation (DIC) is caused by ongoing intravascular thrombin generation with coagulation factor consumption. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a>.)</p><p>However, distinguishing liver disease from DIC can be challenging because the clinical and laboratory findings are similar. Therefore, clinical judgment plays a major role:</p><p class="bulletIndent1"><span class="glyph">●</span>Factor VIII activity levels generally are increased or normal in liver disease (factor VIII is produced in hepatic and non-hepatic endothelial cells) [<a href="#rid67">67</a>]. Therefore, a significant proportion of factor VIII production is unaffected by chronic liver disease. On the other hand, in DIC, consumption of factor VIII causes decreased factor VIII levels. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>D-dimer levels are not useful in liver disease.</p><p></p><p>Importantly, liver disease and DIC may coexist, especially in the setting of infection/sepsis and/or malignancy. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a>.)</p><p class="headingAnchor" id="H1192800948"><span class="h1">MEDICATION MANAGEMENT</span></p><p class="headingAnchor" id="H61501401"><span class="h2">Medications to avoid</span><span class="headingEndMark"> — </span>Individuals with rebalanced hemostasis in the setting of liver disease have increased sensitivity to hemostatic challenges. Patients with well-compensated cirrhosis may tolerate anticoagulation and antiplatelet therapy with little increased risk of bleeding. However, in patients with more advanced liver disease or decompensated cirrhosis, sometimes avoiding medications that increase bleeding and/or thrombotic risk is prudent, unless the benefits clearly outweigh the risks (eg, acute treatment of a thromboembolic event).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulants in some individuals</strong> – We generally adhere to practice guideline recommendations when making decisions regarding venous thromboembolism (VTE) prophylaxis in patients with liver disease while hospitalized [<a href="#rid68">68</a>]. In patients with advanced cirrhosis and high risk for bleeding, it may be reasonable to avoid anticoagulation prophylaxis.</p><p></p><p class="bulletIndent1">We generally avoid anticoagulants in individuals with decompensated Child-Pugh (CTP) class C cirrhosis [<a href="#rid69">69</a>]. Patients with decompensated cirrhosis who require anticoagulation (eg, for VTE or high-risk atrial fibrillation) are treated in an individualized manner with close collaboration between the hepatologist and the hematologist. (See  <a class="medical medical_review" href="/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Child-Pugh classification'</a> and <a class="local">'VTE therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NSAIDs</strong> – We generally avoid nonsteroidal antiinflammatory drugs for routine treatment of pain and/or fever in all patients with cirrhosis. (See  <a class="medical medical_review" href="/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-platelet drugs</strong> – For patients with decompensated cirrhosis, we generally avoid antiplatelet drugs such as <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> or P2Y<sub>12</sub> receptor blockers such as <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, unless cardiovascular benefits exceed the bleeding risks of these agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Over-the-counter medications, herbs, supplements </strong>– For all patients, we provide education regarding over-the-counter medications such as ginkgo biloba that may adversely affect hemostasis. (See  <a class="medical medical_review" href="/d/html/1387.html" rel="external">"Clinical use of ginkgo biloba", section on 'Safety'</a>.)</p><p></p><p>Discussions of over-the-counter hepatotoxins and medications that may exacerbate underlying liver disease are presented separately. (See  <a class="medical medical_review" href="/d/html/3571.html" rel="external">"Drug-induced liver injury"</a> and  <a class="medical medical_review" href="/d/html/3568.html" rel="external">"Drugs and the liver: Metabolism and mechanisms of injury"</a> and  <a class="medical medical_review" href="/d/html/3618.html" rel="external">"Hepatotoxicity due to herbal medications and dietary supplements"</a>.)</p><p class="headingAnchor" id="H2329781734"><span class="h2">Adjustments to anticoagulant dosing</span><span class="headingEndMark"> — </span>Certain anticoagulants are predominantly metabolized by the liver. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Warfarin</strong> – <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> is metabolized by the liver, but dosing is titrated to maintain a therapeutic international normalized ratio (INR). Difficulties can arise when the baseline INR in a cirrhosis patient is not within the normal range, and the target range is unclear. As indicated above, individuals with liver disease often have abnormalities in the INR measurement. (See <a class="local">'Laboratory abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DOACs </strong>– A percentage of hepatic metabolism occurs for all direct oral anticoagulants (DOACs). The product insert should be consulted for more details, as it may determine the optimal choice of anticoagulant for the patient.</p><p></p><p class="bulletIndent1">For the direct factor Xa inhibitors (eg, <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>) and <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>, product information suggests that these drugs should be used with caution or avoidance in patients with Child-Pugh class B or C. These issues are reflected in recommendations for dose adjustment from the US Food and Drug Administration (FDA) and the European Medicines Association (EMA), as illustrated in the table  (<a class="graphic graphic_table graphicRef117823" href="/d/graphic/117823.html" rel="external">table 1</a>). Both clinical and translational data suggest that direct oral anticoagulants (DOACs) may have altered potency in more advanced liver disease, and caution with use in these populations is warranted [<a href="#rid69">69-72</a>]. </p><p></p><p class="bulletIndent1">Use of reversal agents for DOACs has been reported in patients with liver disease [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heparins </strong>– Metabolism of heparins is more complex, but dosing may be simpler because <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> is titrated to maintain the aPTT in a target range. Heparins require the function of antithrombin (AT) to inhibit thrombin and factor Xa  (<a class="graphic graphic_figure graphicRef101832" href="/d/graphic/101832.html" rel="external">figure 2</a>), and, since AT is synthesized in the liver, their activity may be reduced [<a href="#rid74">74</a>]. Anti-factor Xa levels appear to be less reliable in cirrhosis [<a href="#rid75">75</a>]. Low molecular weight (LMW) heparins are usually used for VTE prophylaxis, and prophylactic-dose LMW heparin has been safely used in individuals with cirrhosis [<a href="#rid74">74</a>].</p><p></p><p class="headingAnchor" id="H61498824"><span class="h1">BLEEDING</span></p><p class="headingAnchor" id="H233835367"><span class="h2">General approach to managing bleeding</span><span class="headingEndMark"> — </span>Management of bleeding depends on the location and severity as well as the degree of hemostatic impairment. Variceal bleeding, which accounts for a high percentage of bleeding episodes overall in individuals with cirrhosis (approximately 80 percent), is considered to be predominantly a problem of increased portal pressure and resulting vascular abnormalities rather than a primary hemostatic defect [<a href="#rid76">76</a>]. (See <a class="local">'Variceal bleeding'</a> below.)</p><p>However, nonvariceal bleeding is common and was noted in one in five admissions for decompensated cirrhosis [<a href="#rid77">77</a>].</p><p>Our approach to management depends on how we answer the following questions [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Are other comorbidities present (eg, infection, kidney disease, malignancy)?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>What is the status of fibrinogen (level and function) and is hyperfibrinolysis clinically suggested (especially with delayed mucosal or wound oozing)?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is the patient on medications that alter the risk of bleeding or thrombosis? </p><p></p><p>We base our therapy on which hemostatic defect(s) is thought to be involved, as follows  (<a class="graphic graphic_figure graphicRef102688" href="/d/graphic/102688.html" rel="external">figure 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comorbidities</strong> – Treatable comorbidities can contribute significantly to impaired hemostasis; thus, we address the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infection</strong> – Treat concomitant infections, which may impair hemostasis through effects on vascular function, endogenous heparinoids, and platelets.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute and chronic kidney disease</strong> – Optimize kidney function, since uremia may impair normal platelet function. Data are emerging to suggest that acute kidney injury is associated with altered hemostatic function and may increase the risk of bleeding [<a href="#rid17">17,78,79</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Portal hypertension</strong> – Avoid raising portal pressures (eg, with aggressive transfusions in the absence of active bleeding or shock). Effective volume management including avoiding over-transfusion is essential.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>DIC</strong> – DIC is uncommon, but if suspected, identify and treat the underlying cause.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antithrombic medication </strong>– If the patient is receiving an antithrombotic medication (anticoagulant or antiplatelet agent), decisions about whether to stop and/or reverse the drug are individualized according to the underlying indication and the severity and site of bleeding. </p><p></p><p class="bulletIndent2">We feel more strongly about discontinuation/reversal for individuals with more severe bleeding and less need for anticoagulation (eg, active life-threatening hemorrhage), and we feel more strongly about continuing the anticoagulant for individuals with a greater or obligate need for antithrombotic medications (eg, mechanical heart valve). Individual approaches are often necessary, and working closely with providers across disciplines is essential.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clot formation</strong> – Monitor platelets and fibrinogen levels and a global viscoelastic assay of hemostasis such as thromboelastography (TEG) or thromboelastometry (ROTEM) (see <a class="local">'Coagulation testing'</a> above), if available. Decide which hemostatic products to administer based on the mechanism identified or the deficiency that is contributing to impaired clot formation along with our clinical judgment, rather than a single laboratory measurement  (<a class="graphic graphic_figure graphicRef102688" href="/d/graphic/102688.html" rel="external">figure 3</a>). For the most part, management decisions are unaffected by results of prothrombin time (PT)/international normalized ratio (INR) and aPTT testing, and we avoid the use of isolated PT/INR testing for bleeding assessment. Consultation with a clinician with expertise in this area may be helpful.</p><p></p><p class="bulletIndent1">The value of viscoelastic testing was illustrated in a trial that randomly assigned 96 individuals with cirrhosis and non-variceal upper gastrointestinal bleeding to transfusions guided by TEG or by the PT/INR and platelet count [<a href="#rid80">80</a>]. Both groups had similar control of bleeding and similar length of hospital stay, but compared with the PT/INR/platelet count group, the TEG group received significantly less blood products (median dose of plasma, 880 versus 440 mL; median number of platelet units, 2 versus 1) and experienced fewer transfusion-related adverse events. There was a trend towards better survival in the TEG group that did not reach statistical significance. There are some concerns about the trial design (eg, endoscopic interventions were not described, and transfusions were based on laboratory values rather than clinical endpoints of bleeding). Furthermore, the group selected as standard of care received plasma if their INR exceeded 1.8, a practice not supported by evidence in this population [<a href="#rid2">2</a>]. However, the overall results are encouraging and support the need for further study of this approach. </p><p></p><p class="bulletIndent1">Another trial assessed the use of TEG to guide blood product transfusions compared with conventional markers of PT/INR and platelet count [<a href="#rid81">81</a>]. Only four patients in the TEG group received transfusions, versus 100 percent of the PT/INR/platelet count group. Outcomes including control of bleeding, rebleeding at five days, and mortality were similar between groups. In general, variceal-related bleeding is associated with portal hypertension rather than hemostatic failure, and standard approaches to portal hypertension management and endoscopic treatment are recommended. Routine transfusion of plasma or platelets based on coagulation testing results is not recommended in most cases of acute variceal hemorrhage. (See  <a class="medical medical_review" href="/d/html/1254.html" rel="external">"Overview of the management of patients with variceal bleeding"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vitamin K</strong><strong> </strong>– For individuals with possible <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> deficiency (eg, suspected poor nutrition, cholestatic disease, diarrheal illness, antibiotic use), we administer vitamin K. Vitamin K can be administered (see <a class="local">'Laboratory abnormalities'</a> above) at a dose of 10 mg by intravenous infusion or 10 mg orally per day for three days. The intravenous infusion should be given when there is a concern about absorption and administered slowly (ie, no faster than 1 mg/minute) to reduce the rare but possible risk of anaphylaxis [<a href="#rid82">82</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cryoprecipitate</strong> – If there is active or poorly controlled bleeding, it may be reasonable to administer a dose of Cryoprecipitate (eg, one bag per 10 kg of body weight)  (<a class="graphic graphic_table graphicRef102695" href="/d/graphic/102695.html" rel="external">table 2</a>) while awaiting the results of laboratory testing for correction of presumptive hypofibrinogenemia or dysfibrinogenemia (abnormally functioning fibrinogen) [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent2">For those who can wait for the results of the fibrinogen level, when this becomes available, administer a source of fibrinogen (preferably Cryoprecipitate, which creates a smaller volume load than Fresh Frozen Plasma [FFP]) to maintain a fibrinogen level ≥100 to 120 mg/dL [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent2">Some experts also give Cryoprecipitate for patients with persistent bleeding despite a fibrinogen level ≥100 to 120 mg/dL, based on a presumptive diagnosis of dysfibrinogenemia (typical dose, one bag per 10 kg body weight).</p><p></p><p class="bulletIndent2">The benefits of giving plasma products to individuals with an adequate fibrinogen level must be weighed against the potential for increasing portal pressure, especially in a patient with varices, even if these are not the site of bleeding.</p><p></p><p class="bulletIndent1">We generally avoid more aggressive therapies with a greater risk of promoting thrombosis, such as fibrinogen concentrates, prothrombin complex concentrates (PCCs)  (<a class="graphic graphic_table graphicRef94210" href="/d/graphic/94210.html" rel="external">table 3</a>), or recombinant activated factor VII (rFVIIa), because these products are costly and lack significant supportive evidence. However, these agents may be appropriately used on a case-by-case basis if bleeding continues despite other interventions with caution recognizing the risk from case reports mentioning thromboembolic events and potential DIC [<a href="#rid84">84,85</a>]. In vitro and clinical data are also emerging supporting the use of fibrinogen concentrates during liver transplantation [<a href="#rid86">86,87</a>].</p><p></p><p class="bulletIndent1">We also generally avoid giving FFP due to the large volume load and potential adverse effect on portal pressures. The only instance in which we might consider FFP is for unexplained bleeding that persists after fibrinogen has been repleted with Cryoprecipitate or in patients requiring large numbers of red blood cell (RBC) transfusions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RBCs and platelets</strong> – Monitor complete blood count (CBC) with platelet count.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In active bleeding not related to portal hypertension, transfuse platelets to maintain a platelet count &gt;50,000 to 55,000/microL (&gt;100,000/microL for active, severe, or central nervous system bleeding). Guidelines from various societies regarding platelet count thresholds are summarized in a 2022 review [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Platelet dysfunction (eg, due to uremia or drugs) may be assessed somewhat by viscoelastic testing (eg, TEG, ROTEM); however, this has not been adequately studied in patients with liver disease. If bleeding is severe and platelet function is thought to be impaired, platelet transfusion may be appropriate. (See  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Platelet function disorders'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transfuse RBCs to maintain a hemoglobin level above 7 g/dL. The hemoglobin level may be used to guide RBC transfusions in individuals without ongoing, active bleeding. Higher target levels of hemoglobin could increase portal pressures but may be appropriate in certain circumstances such as with coexisting vascular disease. (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Acute bleeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrinolysis</strong> – Maintain a high suspicion for hyperfibrinolysis, evidenced by delayed bleeding or persistent oozing from mucocutaneous sites. Hyperfibrinolysis may have been overestimated in the past due to reduced clearance of fibrinolytic markers, and its clinical bleeding implications still seem poorly understood [<a href="#rid89">89</a>]. </p><p></p><p class="bulletIndent1">Excess fibrinolytic activity has been reported in the past with saliva and ascites [<a href="#rid90">90</a>]. Thus, a high index of suspicion for hyperfibrinolysis is appropriate in individuals undergoing common dental procedures and with oral/mucosal bleeding. Testing for hyperfibrinolysis using viscoelastic testing such as TEG, ROTEM, or clot lysis times remains challenging. More often, a clinical diagnosis of this phenomenon is necessary.</p><p></p><p class="bulletIndent1">For suspected hyperfibrinolysis based on clinical and/or laboratory features, it is appropriate to administer an antifibrinolytic agent. Available agents include <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> and epsilon <a class="drug drug_general" data-topicid="8561" href="/d/drug information/8561.html" rel="external">aminocaproic acid</a>. These both can be administered intravenously or orally, or in soaked gauze (eg, during dental procedures). Optimal dosing in the setting of liver disease has not been established; use of dosing extrapolated from other settings (eg, anticoagulant-associated bleeding) may be reasonable. </p><p></p><p class="bulletIndent1">A randomized trial in 12,009 patients presenting with acute gastrointestinal bleeding (41 percent with liver disease) who were assigned to receive <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> infusion or placebo found similar five-day mortality rates in both groups [<a href="#rid91">91</a>]. However, there was an increased risk of venous thromboembolism (VTE) in the tranexamic acid group (RR 1.85, 95% CI 1.15-2.98), and on subgroup analysis, the elevated VTE risk was more pronounced in patients with suspected variceal bleeding or liver disease (RR 7.26, 95% CI 1.65-31.9). Caution is advised when using antifibrinolytic agents in patients with liver disease who are bleeding as they may be at risk to become hypercoagulable. (See  <a class="medical medical_review" href="/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Antifibrinolytics and other pro-hemostatic therapies'</a>.)</p><p></p><p class="headingAnchor" id="H61498830"><span class="h2">Variceal bleeding</span><span class="headingEndMark"> — </span>Variceal bleeding is a common and potentially life-threatening complication of liver disease, occurring in 25 to 35 percent of individuals with cirrhosis, and accounting for the majority of cirrhotic bleeding episodes [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/d/html/1254.html" rel="external">"Overview of the management of patients with variceal bleeding"</a> and  <a class="medical medical_review" href="/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage"</a>.)</p><p>Although abnormal coagulation testing is especially concerning in the setting of varices, the major cause of variceal bleeding is thought to be local vascular deformations and hemodynamic changes (eg, increased portal pressure) rather than a bleeding diathesis [<a href="#rid39">39</a>]. Hemostatic mechanisms appear to play only a transient role as evident in the unstable "platelet plug" or nipple sign, which is sometimes evident at the point of varix breach. </p><p>Thus, the most important interventions for prevention and treatment of bleeding involve reducing portal pressure and ligating bleeding lesions. Details are presented separately. (See  <a class="medical medical_review" href="/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage"</a>.)</p><p>Interventions that may be helpful for excessively high INR or excessively low platelet count are noted above. (See <a class="local">'Interventions for hemostatic imbalance'</a> above and <a class="local">'General approach to managing bleeding'</a> above.)</p><p>Use of anticoagulation may be concerning in patients with liver disease presenting with active variceal bleeding. In a retrospective study involving 320 individuals with cirrhosis who were treated with an anticoagulant (mostly <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> to reduce stroke risk in atrial fibrillation), there were 59 episodes of bleeding, and multivariate analysis identified esophageal varices as the greatest independent predictor of bleeding risk (odds ratio [OR] 5.7, 95% CI 1.8-17.7) [<a href="#rid92">92</a>]. Of 14 individuals with variceal bleeding, five (approximately one third) were not receiving a nonselective beta blocker to reduce bleeding risk. These data emphasize the importance of close monitoring for varices, use of interventions to reduce the development of varices, and, for those with varices, the use of prophylactic therapies to reduce the risk of bleeding such a beta blocker or endoscopic variceal ligation. </p><p>However, in a study that evaluated risk of upper gastrointestinal bleeding (variceal and non-variceal) in patients with cirrhosis on anticoagulation compared with a similar cohort of patients not on anticoagulation, outcomes were similar, including failure of endoscopic control of bleeding at five days, need for rescue therapy, and mortality at six weeks [<a href="#rid93">93</a>]. Another study analyzing bleeding risk from endoscopic variceal band ligation in patients with cirrhosis receiving low molecular weight (LMW) heparin found no significant increase in bleeding risk in the group treated with LMW heparin [<a href="#rid94">94</a>].</p><p>In patients with acute variceal bleeding, we recommend holding anticoagulation in the short term during bleeding events. Consideration for reversal of anticoagulation in individual circumstances may be necessary, but the risks and benefits must be weighed carefully. (See  <a class="medical medical_review" href="/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants"</a> and  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR"</a> and  <a class="medical medical_review" href="/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Reversal'</a>.)</p><p>The choice among prophylactic approaches is discussed separately. (See  <a class="medical medical_review" href="/d/html/1245.html" rel="external">"Primary prevention of bleeding from esophageal varices in patients with cirrhosis"</a>.) </p><p>In patients with active bleeding despite these interventions, the use of pro-hemostatic agents may be appropriate as rescue agents in rare instances. However, potential benefits must be weighed against risks such as increased portal pressure with plasma transfusions and increased thrombotic risk with coagulation factor concentrates. We are unaware of studies that have adequately evaluated rFVIIa or PCC in uncontrollable hemorrhage, although they have occasionally been used to try to temporize an unstable situation in case reports. As mentioned above, the use of antifibrinolytic agents during gastrointestinal bleeding did not improve mortality and was associated with a higher risk of VTE.</p><p class="headingAnchor" id="H166552210"><span class="h1">INVASIVE PROCEDURES</span></p><p class="headingAnchor" id="H233835828"><span class="h2">General approach to invasive procedures</span><span class="headingEndMark"> — </span>Management may be particularly challenging in individuals who require invasive procedures [<a href="#rid2">2,5</a>]. Individuals with liver disease may have an increased risk of bleeding with an invasive procedure; the mechanisms may be multifactorial and depend on the type of procedure, its level of bleeding risk, the degree of liver decompensation, and other comorbidities [<a href="#rid5">5,95</a>]. </p><p class="headingAnchor" id="H3176361554"><span class="h3">Assess bleeding risk factors</span><span class="headingEndMark"> — </span>Bleeding risk and risk factors were illustrated in a prospective, multicenter observational study involving 1187 patients with cirrhosis who were admitted to the hospital for 3006 nonsurgical procedures [<a href="#rid95">95</a>]. Procedural-related bleeding was reported in 7 percent of admissions (3.0 percent of procedures). Major bleeding was rare, occurring in 2 percent of admissions (1 percent of procedures). In univariate analysis, pre-procedure prophylaxis (eg, platelet and plasma transfusion) was provided more commonly prior to procedures that resulted in bleeding (19 percent) than procedures without bleeding (7 percent; p=0.001). In multivariate analysis, higher rates of procedure-related bleeding occurred with:</p><p class="bulletIndent1"><span class="glyph">●</span>Higher-risk procedures: odds ratio (OR) 4.64, 95% CI 2.44-8.84</p><p class="bulletIndent1"><span class="glyph">●</span>Higher MELD score at admission: OR 2.37, 1.46-3.86</p><p class="bulletIndent1"><span class="glyph">●</span>Higher body mass index (BMI): OR 1.4, 95% CI 1.10-1.80</p><p></p><p>Pre-procedure international normalized ratio (INR) and platelet count were not predictive of bleeding [<a href="#rid95">95</a>]. Survival analysis indicated increased mortality strongly correlated with procedural related bleeding, particularly patients with major bleeding (HR 12.97, 95% CI 6.42-26.19). </p><p class="headingAnchor" id="H1959830369"><span class="h3">Assess and optimize hemostasis</span><span class="headingEndMark"> — </span>To address this paradigm shift in management of patients with cirrhosis undergoing procedures, international society guidance has emerged from several organizations, such as:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>AASLD </strong>– American Association for the Study of Liver Diseases (AASLD) [<a href="#rid2">2</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><strong>EASL</strong> – European Association for the Study of the Liver (EASL) [<a href="#rid96">96</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><strong>AGA</strong> – American Gastroenterological Association (AGA) [<a href="#rid65">65</a>]</p><p></p><p>In general, these guidance statements recommend against the use of conventional tests of hemostasis (eg, platelet count and INR) and against the use of pre-procedure bleeding prophylaxis in most cases. (See <a class="local">'Society guideline links'</a> below.)</p><p>Common themes that arise include the following, as summarized in guidelines from the AASLD published in 2021 [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Optimizing hemostasis</strong> – We treat comorbidities that can interfere with normal hemostasis, as done for patients with bleeding (see <a class="local">'Bleeding'</a> above). </p><p></p><p class="bulletIndent1">Optimizing kidney function is an important intervention. (See  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults"</a>.) </p><p></p><p class="bulletIndent1">Treating infections is also important, along with correcting <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> deficiency, and others, especially if there is active bleeding. (See <a class="local">'General approach to managing bleeding'</a> above.)</p><p></p><p class="bulletIndent1">While viscoelastic testing does not clearly predict bleeding, we find use of global assays such as thromboelastography (TEG) or thromboelastometry (ROTEM) often can reassure operators prior to many procedures that hemostasis is intact. Of note, we do <strong>not</strong> administer Fresh Frozen Plasma (FFP) prior to procedures in individuals with liver disease, regardless of laboratory values. (See <a class="local">'Laboratory abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment of hemostasis</strong> – Accurate assessment of hemostasis is limited using traditional and global measures of hemostasis. However, viscoelastic testing prior to procedures has been shown to reduce need for prophylaxis. </p><p></p><p class="bulletIndent1">The value of using a measure of global clot formation to guide blood product use was demonstrated in a trial that randomly assigned 60 patients with cirrhosis who were undergoing an invasive procedure to be managed using thromboelastography (TEG) or according to standard hospital protocol [<a href="#rid55">55</a>]. Patients assigned to the TEG arm received FFP if the reaction time (r) was &gt;40 minutes (normal range for this study, 12 to 26 minutes) and platelets if the maximum amplitude (MA) was &lt;30 mm  (<a class="graphic graphic_figure graphicRef100078" href="/d/graphic/100078.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef74954" href="/d/graphic/74954.html" rel="external">table 4</a>). Those assigned to standard protocol received FFP for international normalized ratio (INR) &gt;1.8 and platelets for a count &lt;50,000/microL. The overall use of blood products was lower in the TEG group (17 versus 100 percent). There was no bleeding in the TEG group and one episode of bleeding in the control group (hemoperitoneum following large-volume paracentesis). This study highlights the difficulty in assessing need for prophylactic therapy without a standardized and accurate measure of in vivo hemostasis [<a href="#rid97">97,98</a>].</p><p></p><p class="bulletIndent1">In a series of 72 patients with decompensated cirrhosis, TEG findings accurately discriminated between those with major life-threatening bleeding (all had an MA &lt;30 mm) and mild or no bleeding (MA &gt;30 mm), whereas conventional coagulation testing and platelet counts were not useful in determining bleeding risk [<a href="#rid99">99</a>]. Two subsequent studies using viscoelastic testing in patients with cirrhosis also demonstrated that value of viscoelastic testing prior to central venous line placement and high-risk invasive procedures to reduce prophylactic transfusion; there were no bleeding events in either study [<a href="#rid56">56,57</a>]. Only one of these three trials incorporated a restrictive arm that did not use pre-procedure prophylaxis. Future studies should include restrictive arms with viscoelastic testing prior to determine the utility of these tests in predicting bleeding and to establish useful, clinically relevant parameters.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for platelet transfusion</strong> – Platelet transfusions are often given to individuals with severe thrombocytopenia (platelet count &lt;50,000/microL) who require an urgent or emergency procedure with a high bleeding risk such as spinal surgery, cardiac surgery, liver biopsy, removal of a large gastrointestinal polyp, or transjugular intrahepatic portosystemic shunt (TIPS) procedure. In a study examining thrombin generation using a thrombin generation assay, platelet counts above 56,000 were associated with normal thrombin production [<a href="#rid100">100</a>]. Results from prior retrospective studies provided conflicting data regarding the risk of bleeding in the setting of thrombocytopenia [<a href="#rid101">101,102</a>]. A large prospective multicenter study from 2023 demonstrated that platelet count prior to a procedure was not a significant predictor of bleeding [<a href="#rid95">95</a>]. While prophylactic platelet transfusions were provided prior to only 2.4 percent of procedures, those procedures in which platelets were transfused were associated with more bleeding. </p><p></p><p class="bulletIndent1">There is a clear confounding relationship between thrombocytopenia and the degree of hepatic decompensation, with progressive thrombocytopenia worsening in more advanced liver disease [<a href="#rid95">95</a>]. In addition, bleeding events with procedures are rare, and past studies have lacked control arms in which prophylactic platelet transfusions are omitted. </p><p></p><p class="bulletIndent1">We advocate an individualized approach for each patient and the specific procedure type when planning for procedures. In general, AASLD, EASL, and AGA guidance recommends avoiding platelet transfusions or thrombopoietin receptor agonists (TPO-RAs) prior to most procedures [<a href="#rid2">2,65,96</a>]. However, EASL guidance recommends considering supportive approaches in patients with severe thrombocytopenia who are undergoing high risk procedures where local hemostasis cannot be achieved on a case-by-case basis [<a href="#rid96">96</a>]. Selected platelet count thresholds for specific invasive procedures are described separately. (See  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Preparation for an invasive procedure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other interventions to raise the platelet count</strong> – Thrombopoietin receptor agonists (TPO-RAs) increase the platelet count by stimulating the TPO receptor. Their effect is transient and takes several days to be effective. We consider using TPO-RA in an individual with liver disease and severe thrombocytopenia who is undergoing a scheduled invasive procedure with a very high bleeding risk (eg, spinal surgery, cardiac surgery, large polypectomy), provided there is sufficient time (10 to 13 days) to start the drug and to document an increase in the platelet count to ≥50,000 microL. </p><p></p><p class="bulletIndent1">Clinicians may reasonably use restrictive strategies without administering a TPO-RA in most scenarios, such as close observation, depending on the bleeding risk of the procedure [<a href="#rid2">2</a>]. As an example, we would not use a TPO-RA for a patient undergoing a low-risk procedure such as paracentesis, routine endoscopy, or central line placement, as the risks and burdens are likely to outweigh the benefits. More urgent or emergency procedures in the setting of severe thrombocytopenia are likely to require platelet transfusions, since TPO-RAs take several days to raise the platelet count. Recent guidelines recommend against routine use of TPO-agonists to correct thrombocytopenia in patients with cirrhosis prior to procedures, including patients critically ill in the intensive care unit setting [<a href="#rid2">2,64,65,103</a>].</p><p></p><p class="bulletIndent1">Two TPO-RAs are approved for use in patients with chronic liver disease and thrombocytopenia prior to undergoing procedures. The clinical trials that led to their approval demonstrated clear efficacy and safety in raising platelet counts; however, the trials were not designed to assess overall bleeding risk in thrombocytopenia, as they lacked restrictive cohorts who did not receive a TPO-RA or platelet transfusion. Furthermore, bleeding events were rare, and most of the procedures carried a low risk for bleeding.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="117929" href="/d/drug information/117929.html" rel="external">Avatrombopag</a> – In a pair of randomized trials that included 435 individuals with chronic liver disease and severe thrombocytopenia who required an invasive procedure, the TPO-RA avatrombopag was demonstrated to reduce the need for platelet transfusion (platelet transfusions given in 12 to 34 percent of avatrombopag-treated patients versus 64 to 66 percent of placebo-treated patients) [<a href="#rid104">104</a>]. There was no increase in complications (one case of portal vein thrombosis two weeks after completion of therapy in the avatrombopag group, one episode of pulmonary embolism and one myocardial infarction in the placebo group) or other serious safety signals. Avatrombopag was approved by the US Food and Drug Administration (FDA) in 2018 for the treatment of thrombocytopenia in adults with chronic liver disease who are undergoing a scheduled procedure [<a href="#rid105">105</a>]. The drug should be started 10 to 13 days before the procedure and taken for five days. The effect will wane over time and the platelet count is expected to gradually return to baseline once the drug is discontinued; thus, close attention should be paid to the timing of administration relative to the procedure. The dose of avatrombopag is based on the patient's platelet count (&lt;40,000/microL: 60 mg; 40,000 to 50,000/microL: 40 mg).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="118602" href="/d/drug information/118602.html" rel="external">Lusutrombopag</a> – Three randomized trials (as yet unpublished) evaluated use of the TPO-RA lusutrombopag in individuals with chronic liver disease and thrombocytopenia undergoing a scheduled invasive procedure. Compared with placebo, lusutrombopag greatly increased the likelihood of avoiding a platelet transfusion (13 to 29 percent avoided platelet transfusions with placebo versus 78 to 65 percent with lusutrombopag) [<a href="#rid106">106</a>]. The dose was 3 mg daily for up to seven days prior to the scheduled procedure. Lusutrombopag received approval in 2015 in Japan and in 2018 in the United States for this indication (raising the platelet count in individuals with severe liver disease and thrombocytopenia prior to an invasive procedure) [<a href="#rid106">106,107</a>].</p><p></p><p class="bulletIndent1">Additional information about these and other TPO-RAs is presented separately. (See  <a class="medical medical_review" href="/d/html/6671.html" rel="external">"Clinical applications of thrombopoietic growth factors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for plasma products</strong> – We do <strong>not</strong> routinely administer FFP or Cryoprecipitate to "correct" the PT/INR value prior to a procedure, because several large reviews of available evidence have shown no clinical benefit [<a href="#rid3">3,13,108-111</a>]. The underpinnings of INR as a target and measure of bleeding risk (outside of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> therapy) do not apply to patients with cirrhotic coagulopathy, which has a completely different pathophysiology than that seen in warfarin anticoagulation.</p><p></p><p class="bulletIndent1">Additional risks and disadvantages of giving FFP include transfusion reactions, volume overload (and associated increases in portal pressure, especially in individuals with varices), and infection. Administration of FFP also may create a significant delay while awaiting repeated laboratory testing of the PT/INR [<a href="#rid83">83</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reducing vascular engorgement</strong> – We avoid engorgement of the collateral bed as much as possible by limiting volume expansion [<a href="#rid39">39</a>]. Because of the mucosal engorgement of the capillary bed in the tributaries of the portal venous system, we recommend optimization of portal hypertension and careful attention specifically to procedures involving gut mucosa (eg, endoscopy).</p><p></p><p class="headingAnchor" id="H166552254"><span class="h2">Non-surgical invasive procedures</span><span class="headingEndMark"> — </span>Procedural-related bleeding in cirrhosis is overall rare, and available tests of hemostasis do not accurately predict bleeding prior to procedures [<a href="#rid95">95</a>]. Investigators have routinely grouped low- and high-risk procedures together in studies assessing bleeding. When bleeding does occur, it is not clear that prophylaxis would have prevented it (eg, laceration of an artery during paracentesis). </p><p>We advocate for individual assessment of each patient's circumstances and bleeding risk specific to the procedure. In general, we favor approaches to minimize unnecessary use of prophylaxis except in high-risk situations. </p><p>In addition to addressing treatable comorbidities that may affect hemostasis, we use the following procedure-specific interventions:</p><p class="headingAnchor" id="H2635583513"><span class="h3">Paracentesis</span><span class="headingEndMark"> — </span>Diagnostic and therapeutic paracentesis carries a low risk for bleeding complications. In most cases, we do not use pre-procedure prophylaxis, which is consistent with guidelines in the United States [<a href="#rid2">2,112,113</a>]. Exceptions include patients who have bled before with paracentesis or who have known or suspected hyperfibrinolysis or some other overtly evident bleeding such as mucosal bleeding. With proper needle and cannula placement, bleeding in this situation is usually venous, from the collateral bed of the abdominal wall venous system. Thus, avoiding engorgement of the collateral bed (as with plasma transfusions) is important to minimize bleeding risk. Studies suggest that individualized approaches are necessary, bleeding risk is not completely uniform, and bleeding risk likely depends on dynamic factors for each patient [<a href="#rid114">114</a>]. (See <a class="local">'Variceal bleeding'</a> above.)</p><p class="headingAnchor" id="H2650938385"><span class="h3">Thoracentesis</span><span class="headingEndMark"> — </span>Thoracentesis is commonly performed in individuals with advanced liver disease and is considered a low-risk procedure [<a href="#rid115">115</a>]. Sparse data exist to establish overall bleeding risk, and we do not routinely recommend use of prophylaxis prior to thoracentesis. One retrospective study examined patients with perceived "coagulopathy" undergoing a total of 1009 thoracentesis (portion with liver disease not identified) and found no significant difference with or without prophylaxis (no bleeding events in the non-prophylaxis group) [<a href="#rid116">116</a>]. </p><p class="headingAnchor" id="H3493118914"><span class="h3">Liver biopsy</span><span class="headingEndMark"> — </span>The use of liver biopsy for staging fibrosis is declining, but biopsy remains an essential diagnostic tool in many conditions. It always raises concerns about bleeding, especially in patients with suspected coagulopathy and low platelets, and even more so in those with added risks such as chronic kidney disease or increased risk of volume overload. However, a review of 200 patients in whom "liver bleeding time" was evaluated at the time of liver biopsy found that there was no correlation between the degree of bleeding and any measure of hemostasis tested (eg, prothrombin time [PT], platelet count, whole blood clotting time) [<a href="#rid117">117</a>].</p><p>There is no well-defined platelet cut-off that can be used to determine need for platelet correction prior to liver biopsy in patients with chronic liver disease. In cases where platelet correction is felt to be necessary, a careful assessment of patient medications and comorbidities is essential. Providing a TPO-RA or platelet transfusions to increase the platelet count to &gt;50,000/microL can be considered in high-risk patients for whom there is concern for potential bleeding. Other considerations include transfusing Cryoprecipitate when fibrinogen is low and perceived bleeding risk is high, to raise the fibrinogen to &gt;120 mg/dL. </p><p>Transvenous biopsy is an alternative approach in particularly high-risk patients, although the quality of specimens is sometimes limiting and overall complication rates are similar to percutaneous biopsy, albeit usually in a higher risk population. Our practice is consistent with guidance from the American Association for the Study of Liver Diseases, which suggests an individualized approach [<a href="#rid2">2,118</a>].</p><p class="headingAnchor" id="H2208520060"><span class="h3">Dental extractions</span><span class="headingEndMark"> — </span>Dental extractions can usually be performed using local hemostatic measures alone (without systemic interventions to enhance hemostasis) [<a href="#rid119">119,120</a>]. One trial randomly assigned 43 patients with cirrhosis awaiting liver transplantation who had an INR 2.0 to 3.0 and/or a platelet count ≤50,000/microL to receive intranasal DDAVP (300 mcg) or transfusions (FFP, 10 mL/kg and/or one unit of single-donor platelets, based on INR and platelet count) prior to the dental procedure [<a href="#rid121">121</a>]. Hemostasis was similar in the two groups, and adverse effects were less with DDAVP (no major events versus one bleeding and one allergic reaction in the transfusion group). This trial highlights the need for placebo arms to assess baseline bleeding risk. Use of topical gauze soaked in <a class="drug drug_general" data-topicid="8561" href="/d/drug information/8561.html" rel="external">aminocaproic acid</a> is a useful adjunct to prevent delayed bleeding.</p><p class="headingAnchor" id="H1163324001"><span class="h3">Palliative drain placement</span><span class="headingEndMark"> — </span>In some situations involving terminal care of a patient with cirrhosis, indwelling drains may be used to better control refractory ascites. In these situations, which are often accompanied by a degree of kidney failure, prophylactic therapy may be warranted, especially if a tunneled catheter is to be placed, due to increased risk of trauma to the portal venous collateral bed of the abdominal wall.</p><p class="headingAnchor" id="H166552260"><span class="h2">Major surgery</span><span class="headingEndMark"> — </span>Surgical bleeding is separate from the above discussion of non-surgical, procedure-related bleeding. Interventions for patients who require major surgery, including liver transplant, must be individualized. Often surgical bleeding is directly instigated and managed by local surgical measures. </p><p>Increasingly, global measures of hemostasis such as TEG and ROTEM are being used by the anesthesiologist to guide optimal hemostatic measures. Global viscoelastic tests may assist with management of bleeding during the operation and in the post-operative period. (See <a class="local">'General approach to managing bleeding'</a> above.)</p><p>In the absence of these tests, we would recommend a similar approach as outlined above, which includes optimizing the platelet count (in severe thrombocytopenia), fibrinogen level, and comorbidities such as reduced kidney function; and avoiding the use of INR values to guide therapy. </p><p>As with all procedures, avoidance of volume expanding the portal collateral circulation is essential to optimize safety. In some cases, especially when there are abundant collaterals in the operative field (such as colon resection or uterine resection), preoperative transjugular intrahepatic portosystemic shunt (TIPS) may be appropriate in selected patients to decrease flow in portal collaterals. Individual assessment and subspeciality collaboration are recommended when this approach is sought, as data to support this practice are sparse. (See  <a class="medical medical_review" href="/d/html/1265.html" rel="external">"Overview of transjugular intrahepatic portosystemic shunts (TIPS)"</a>.)</p><p class="headingAnchor" id="H61498878"><span class="h1">PORTAL VEIN THROMBOSIS (PVT)</span><span class="headingEndMark"> — </span>Partially or completely occlusive thrombosis in the portal circulation occurs with an estimated incidence of approximately 5-16 percent per year in patients with stable cirrhosis without liver cancer [<a href="#rid122">122,123</a>]. PVT occurs more frequently in more advanced cirrhosis. PVT may be acute or chronic. Focal left or right branch PVT is relatively more common and often clinically silent, although its development may contribute to overall organ atrophy. (See  <a class="medical medical_review" href="/d/html/88016.html" rel="external">"Epidemiology and pathogenesis of portal vein thrombosis in adults", section on 'Epidemiology'</a>.)</p><p>The mechanism of PVT in liver disease is likely to involve a combination of factors, including reduction in natural anticoagulants, decreased portal blood flow, and endothelial dysfunction, along with other prothrombotic comorbidities in some individuals (eg, genetic predisposition, hepatocellular cancer) [<a href="#rid124">124</a>]. (See <a class="local">'Prothrombotic changes'</a> above and  <a class="medical medical_review" href="/d/html/88016.html" rel="external">"Epidemiology and pathogenesis of portal vein thrombosis in adults", section on 'Pathogenesis'</a>.)</p><p>The clinical significance of PVT continues to be debated. It is unclear whether development of PVT represents an epiphenomenon from progressive portal hypertension or a treatable condition in cirrhosis in the absence of overt symptoms. The need for therapy is clearer when there are obvious related symptoms or in the setting of liver transplantation candidacy. The role of the portosystemic collateral bed may also obscure the effects of PVT as slow flow due to shunting (steal) through large collaterals may be as significant whether or not associated with actual thrombosis [<a href="#rid125">125</a>].</p><p class="headingAnchor" id="H166552800"><span class="h2">PVT risk factors</span><span class="headingEndMark"> — </span>The risk of PVT is increased in individuals with cirrhosis, and PVT occurs more frequently in those with greater disease severity (eg Child-Pugh class C) [<a href="#rid126">126</a>].</p><p>In addition to the severity of liver disease, other factors that increase PVT risk include the presence of hepatocellular cancer and genetic susceptibility factors (eg, inherited thrombophilia). Case-control studies have also noted that patients with cirrhosis and PVT have a higher incidence of factor V Leiden mutation. In the randomized trial of <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> versus no therapy, 2 of 70 patients (3 percent) had a factor V Leiden and none had a prothrombin G20210A mutation [<a href="#rid122">122</a>]. The role of testing for genetic thrombophilic factors in this population is not well-defined and the role of testing should be determined on an individual basis [<a href="#rid124">124,127</a>].</p><p class="headingAnchor" id="H166552806"><span class="h2">PVT prophylaxis</span><span class="headingEndMark"> — </span>Prevention of PVT in individuals with liver disease focuses on optimizing hepatic function, reducing portal venous pressure, and increasing portal flow, which diminishes stasis. (See  <a class="medical medical_review" href="/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'General management'</a> and  <a class="medical medical_review" href="/d/html/1265.html" rel="external">"Overview of transjugular intrahepatic portosystemic shunts (TIPS)"</a>.)</p><p>The role of prophylactic anticoagulation is uncertain, and we do not use it outside of a separate indication. However, if the patient has a separate indication for anticoagulation, we do not consider cirrhosis to be a contraindication for the use of an anticoagulant, following assessment and treatment of high-risk varices if present. </p><p>A randomized trial assessed anticoagulation to prevent PVT was conducted using fixed-dose low molecular weight (LMW) heparin (<a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> 4000 international units subcutaneously once daily) versus no therapy for one year in 70 patients with advanced cirrhosis (Child-Pugh class B, mean model for end-stage liver disease [MELD] score 13) [<a href="#rid122">122,128</a>]. Portal vein patency was documented prior to entry. Findings included the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A greater reduction in the incidence of PVT by ultrasound and computed tomography (the primary endpoint) was seen with <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> compared with controls at all time points: one year (0 versus 17 percent), two years (0 versus 28 percent), or study end (approximately three and a half years; 9 versus 28 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary endpoints including hepatic decompensation (eg, development of ascites, encephalopathy, peritonitis) were also less frequent with <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> (12 versus 59 percent), and there was a modest but significant improvement in survival (8 versus 13 deaths).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complications of <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> were minimal, with no episodes of severe bleeding and one episode of thrombocytopenia that led to discontinuation of enoxaparin. Two enoxaparin-treated patients and one control patient had variceal bleeding.</p><p></p><p>It should be noted that this trial was small, focused on patients with moderate disease (mostly Child-Pugh class B or early C), and had methodological concerns including premature data analysis, atypical patient population, and un-blinding [<a href="#rid122">122,128,129</a>]. No study has confirmed or refuted the findings of this single trial.</p><p>Further studies are essential to confirm these results in larger and more heterogenous cohorts; trials that may confirm or refute these results are enrolling [<a href="#rid130">130</a>]. </p><p>As noted above, if a patient has another indication for anticoagulation, we typically counsel that cirrhosis in itself would not be a contraindication following assessment for risk factors (eg, severe thrombocytopenia) and treatment of high-risk varices if present.</p><p class="headingAnchor" id="H166552812"><span class="h2">PVT treatment</span><span class="headingEndMark"> — </span>Treatment of PVT is discussed in detail in separate topic reviews. While controversial, evidence summarized in a 2017 meta-analysis suggests that anticoagulation is a safe and effective therapy for PVT in select patients with cirrhosis [<a href="#rid131">131</a>]. This subject is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3579.html" rel="external">"Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/d/html/88014.html" rel="external">"Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H61498885"><span class="h1">VENOUS THROMBOEMBOLISM (VTE)</span><span class="headingEndMark"> — </span>Management may be particularly challenging in individuals who require anticoagulant therapy [<a href="#rid2">2,5</a>]. Exclusion of patients with an underlying coagulopathy from the majority of VTE trials has led to an extreme paucity of data regarding risks, prevention, and treatment of peripheral deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients with severe liver disease.</p><p class="headingAnchor" id="H61499076"><span class="h2">VTE risk</span><span class="headingEndMark"> — </span>Several retrospective studies have evaluated the risk of VTE in individuals with chronic liver disease. Although the rates of VTE differ across studies, it is clear that patients with cirrhosis are at risk for VTE. Notably, VTE-associated mortality is significantly increased in patients with cirrhosis [<a href="#rid132">132,133</a>]. A single-center study found an increased risk of mortality in patients with cirrhosis who developed VTE compared with controls (7 versus 3 percent). The 30-day mortality among patients with cirrhosis was 7 percent for those with DVT and 35 percent for those with PE. Data from a large registry trial suggest patients with cirrhosis who are treated with anticoagulation have a high risk of VTE recurrence and a high risk of mortality related to bleeding [<a href="#rid134">134</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Any severity of liver disease</strong> – The risk of VTE was evaluated in a 2015 meta-analysis of 14 studies involving patients with liver disease that found a pooled incidence VTE of 1 percent (DVT: 0.6 percent; PE: 0.28 percent) [<a href="#rid135">135</a>]. In a 2016 meta-analysis focused solely on hepatitis C virus (HCV) infection that included over 100,000 HCV-infected individuals and over 8 million controls, the odds ratio (OR) for VTE was 1.9 (95% CI 1.4-2.6) [<a href="#rid136">136</a>]. In a 2009 retrospective study involving almost 9,000,000 patients hospitalized over an approximately 25-year period, the prevalence of VTE was 0.6 percent in those with alcoholic liver disease and 0.9 percent in those with nonalcoholic liver disease [<a href="#rid137">137</a>]. These were considered lower than seen in most patients hospitalized with other conditions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cirrhosis</strong> – Patients with cirrhosis may have a higher risk of VTE. This was demonstrated in a meta-analysis of 11 studies involving patients with cirrhosis that found an increased risk of VTE compared with controls (OR 1.7, 95% CI 1.3-2.2) [<a href="#rid138">138</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 2011 database review of 449,798 hospitalizations for cirrhosis, 8231 were for VTE (1.8 percent) [<a href="#rid139">139</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 2015 review from an insurance database in Taiwan that compared 2223 patients with cirrhosis versus 22,230 matched controls, the adjusted hazard ratio (HR) of VTE in patients with cirrhosis was 1.71 (95% CI 1.05-2.78) [<a href="#rid140">140</a>]. The risk was especially high in those with advanced cirrhosis.</p><p></p><p>As expected, additional comorbidities and/or other VTE risk factors appear to further increase VTE risk. Patients with non-alcohol steatohepatitis-related cirrhosis may be at an increased risk to develop VTE [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H61499090"><span class="h2">VTE prophylaxis</span><span class="headingEndMark"> — </span>VTE prophylaxis is appropriate for high-risk hospitalized medical and surgical patients with liver disease, similar to individuals hospitalized with other acute conditions [<a href="#rid68">68,133</a>]. Hospitalized patients with liver disease have multiple risk factors for VTE. Risk assessment models such as the Padua Prediction Score or IMPROVE score can be used to assess risk of VTE in hospitalized patients with liver disease [<a href="#rid141">141,142</a>]. </p><p>VTE prophylaxis has historically been underused in this population, which is likely due to concerns about increased bleeding risk and/or the mistaken assumption that individuals with severe liver disease are "auto-anticoagulated" based on the finding of a prolonged prothrombin time (PT). Literature in this area is limited, and studies are small and underpowered to assess the efficacy and safety of VTE prophylaxis.</p><p>The safety of VTE prophylaxis in patients with cirrhosis was evaluated in a study of 235 patients with chronic liver disease (mean model for end-stage liver disease [MELD] score, 16.2) who were hospitalized 355 times and received VTE prophylaxis as part of an institution-wide protocol [<a href="#rid143">143</a>]. Approximately three-fourths received <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a>, and the remainder received a low molecular weight (LMW) heparin. The use of VTE prophylaxis was associated with nine episodes of gastrointestinal bleeding (2.5 percent), most of which were minor (&lt;2 g/dL decline in hemoglobin), and two episodes of heparin-induced thrombocytopenia (HIT; 0.5 percent). Five patients (1.4 percent) developed a VTE despite prophylaxis.</p><p>A retrospective cohort study compared hospitalized patients with cirrhosis who did or did not receive VTE prophylaxis [<a href="#rid144">144</a>]. Out of 600 hospital admissions, VTE prophylaxis was used in 49 percent. The rates of bleeding and VTE were similar in the two groups, including in-hospital bleeding events (8 versus 6 percent), gastrointestinal bleeding (approximately 3 percent in both groups), and new VTE (approximately 2 percent in both groups). On subgroup analysis, patients receiving <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> had a higher risk of bleeding (OR 2.38, 95% CI 1.15-4.94), whereas low molecular weight (LMW) heparin was not associated with bleeding.</p><p>Exceptions to the use of VTE prophylaxis may include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Low risk for VTE (eg, the individual is ambulatory)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased risk for bleeding, such as severe thrombocytopenia (generally considered as a platelet count &lt;50,000/microL; can be more or less depending on specific patient features)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Active bleeding or other contraindication</p><p></p><p>Close discussion among treating clinicians is appropriate for individualizing therapy.</p><p>Lower extremity compression devices are less likely to be effective in individuals with significant peripheral edema, although this issue has not been studied.</p><p>Additional discussions regarding the indications, contraindications, timing, and dosing of prophylactic anticoagulation, and alternatives (eg, mechanical interventions), are presented in detail separately. (See  <a class="medical medical_review" href="/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a> and  <a class="medical medical_review" href="/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p class="headingAnchor" id="H61499097"><span class="h2">VTE therapy</span><span class="headingEndMark"> — </span>Therapy for VTE may be required in patients with liver disease. This may be complicated by concerns about risk of bleeding, difficulty monitoring the degree of anticoagulation in an individual with abnormal clotting times at baseline, and the lack of evidence to support a specific anticoagulant, dose, or duration of therapy. The majority of studies examining therapeutic anticoagulation have been in patients with cirrhosis and portal vein thrombosis. (See <a class="local">'Portal vein thrombosis (PVT)'</a> above.)</p><p>In the absence of such evidence, our general practice is to balance the risks and benefits of anticoagulation overall in the patient. This may entail screening endoscopy if this has not been performed already.</p><p class="bulletIndent1"><span class="glyph">●</span>For individuals with varices and advanced cirrhosis, overall bleeding risk is likely increased. However, some individuals have a pressing indication for anticoagulation (eg, large pulmonary embolism) and require prompt therapy; these individuals should have proper variceal screening and bleeding risk reduction prior to the initiation of therapy. In a study that evaluated risk of upper gastrointestinal bleeding in patients with cirrhosis on anticoagulation compared with a similar cohort of patients not on anticoagulation, outcomes were similar, including failure of endoscopic control of bleeding at five days, need for rescue therapy, and mortality at six weeks [<a href="#rid93">93</a>]. Decisions regarding the timing of therapy and type of anticoagulation should be made with multidisciplinary discussions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For individuals without significant varices or high-risk contraindications to anticoagulation who develop a VTE, we generally use anticoagulation with LMW heparin, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, or, increasingly, a direct acting oral anticoagulant (DOAC; eg, <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>) [<a href="#rid145">145-147</a>]. The choice of anticoagulant and duration of therapy is usually determined through collaboration of hepatologists and hematologists. Individual characteristics of the patient, including but not limited to degree of hepatic decompensation (Child-Pugh score), comorbidities, platelet count, presence of varices, frailty, and risk of falls all factor into the decision of the optimal therapy. (See <a class="local">'Adjustments to anticoagulant dosing'</a> above.)</p><p></p><p>Monitoring depends on the anticoagulant used and the patient's baseline testing [<a href="#rid124">124</a>]. If their baseline international normalized ratio (INR) is within the normal range, then <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> can be used conventionally. However, the INR often is outside of the normal range and obscures appropriate target ranges; this situation warrants consideration of the use of other anticoagulants.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients receiving therapeutic doses of a LMW heparin, anti-factor Xa activity can be measured; however, this is controversial [<a href="#rid148">148</a>]. (See  <a class="medical medical_review" href="/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Heparin resistance/antithrombin deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those receiving <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, if the baseline is normal, then target INR levels should range from 2.0 to 3.0. We have used warfarin in patients with baseline INR prolongation (eg, patients with prosthetic heart valves or atrial fibrillation). However, data are lacking on target INR, and more study is needed to better guide therapy with warfarin and DOACs in this setting.</p><p></p><p>The relative safety of therapeutic anticoagulation for DVT and PE in patients with decompensated cirrhosis has not been determined. However, based on studies in individuals with portal vein thrombosis, bleeding risks appear to be relatively low in highly selected populations [<a href="#rid149">149-152</a>]. (See <a class="local">'PVT treatment'</a> above.)</p><p>Of note, some individuals with liver disease may require adjustment of doses of heparin products due to mild antithrombin deficiency. However, monitoring heparin efficacy in cirrhosis is often challenging and use of aPTT and anti-factor X levels are controversial. (See  <a class="medical medical_review" href="/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Heparin resistance/antithrombin deficiency'</a>.)</p><p class="headingAnchor" id="H61498836"><span class="h1">ACUTE LIVER FAILURE</span><span class="headingEndMark"> — </span>Hemostatic profiles in patients with acute liver failure (ALF) do not behave in a similar manner to those with chronic liver diseases. Studies have shown intact thrombin generation capacity in the setting of acute liver failure [<a href="#rid153">153</a>]. Despite an elevated international normalized ratio (INR), thromboelastography has demonstrated normal hemostasis in this population [<a href="#rid48">48</a>]. One study examined the rate of bleeding with intracranial pressure monitoring and found that bleeding rates were similar in the group that received INR correction with significant amounts of Fresh Frozen Plasma (FFP) transfused as the group that did not [<a href="#rid154">154</a>]. In an analysis of a cohort of 1770 patients from the ALF Study Group registry, 187 (11 percent) had bleeding events [<a href="#rid49">49</a>]. While the majority of events were spontaneous and unrelated to procedures, 20 intracranial hemorrhages occurred (10 spontaneous and 10 related to intracranial pressure monitor insertion). This study emphasizes the high mortality associated with ALF.</p><p>Optimizing hemostasis is one of many aspects of the management of acute liver failure; additional testing and interventions are presented in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children</strong> – (See  <a class="medical medical_review" href="/d/html/16142.html" rel="external">"Acute liver failure in children: Etiology and evaluation"</a> and  <a class="medical medical_review" href="/d/html/83172.html" rel="external">"Acute liver failure in children: Management, complications, and outcomes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adults</strong> – (See  <a class="medical medical_review" href="/d/html/3574.html" rel="external">"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3570.html" rel="external">"Acute liver failure in adults: Management and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver transplantation</strong> – (See  <a class="medical medical_review" href="/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation"</a>.)</p><p></p><p class="headingAnchor" id="H2526823199"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115541.html" rel="external">"Society guideline links: Cirrhosis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114134.html" rel="external">"Society guideline links: Gastrointestinal bleeding in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/116327.html" rel="external">"Society guideline links: Nonalcoholic fatty liver disease"</a> and  <a class="medical medical_society_guidelines" href="/d/html/116328.html" rel="external">"Society guideline links: Alcohol-associated liver disease"</a>.)</p><p class="headingAnchor" id="H2944559111"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15380.html" rel="external">"Patient education: Cirrhosis (The Basics)"</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4574.html" rel="external">"Patient education: Cirrhosis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H61498892"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Liver disease leads to a form of "rebalanced" hemostasis, in which diminished hepatic function leads to both procoagulant and anticoagulant effects. Patients with severe liver disease and abnormalities of coagulation testing should not be assumed to be "auto-anticoagulated," because standard coagulation testing does not assess prothrombotic and fibrinolytic changes. (See <a class="local">'Physiologic effects of hepatic dysfunction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory assessment</strong> – Individuals with liver disease frequently have abnormalities in routine laboratory tests of coagulation. If accurate testing of hemostasis is required, it might be more helpful to use comprehensive viscoelastic testing such as thromboelastography (TEG) or thromboelastometry (ROTEM)  (<a class="graphic graphic_figure graphicRef100078" href="/d/graphic/100078.html" rel="external">figure 1</a>) to guide therapy; clinically, this testing is generally confined to perioperative transfusion guidance in patients undergoing liver transplantation. (See <a class="local">'Laboratory abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleeding</strong> – Management of bleeding depends on the location and severity as well as the degree of hemostatic impairment. (See <a class="local">'Bleeding'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonvariceal </strong>– For nonvariceal bleeding, our general approach includes addressing treatable comorbidities and assessing the platelet count, fibrinogen levels, and a global assay of hemostasis such as TEG or ROTEM. We give <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> if the patient history suggests possible deficiency, transfuse platelets to maintain a platelet count &gt;50,000 in active bleeding and administer a source of fibrinogen (preferably Cryoprecipitate, which creates a smaller volume load than Fresh Frozen Plasma [FFP]  (<a class="graphic graphic_table graphicRef102695" href="/d/graphic/102695.html" rel="external">table 2</a>)) to maintain a fibrinogen level ≥100 to 120 mg/dL, and administer an antifibrinolytic agent (<a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> or epsilon <a class="drug drug_general" data-topicid="8561" href="/d/drug information/8561.html" rel="external">aminocaproic acid</a>) if excessive fibrinolysis is suspected  (<a class="graphic graphic_figure graphicRef102688" href="/d/graphic/102688.html" rel="external">figure 3</a>). (See <a class="local">'General approach to managing bleeding'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Variceal </strong>– For variceal bleeding, the major cause is increased portal pressure rather than a bleeding diathesis, and the most important interventions for prevention and treatment of bleeding involve reducing portal pressure and ligating bleeding lesions. Hemostatic mechanisms appear to play only a transient role; however, anticoagulation may contribute to bleeding risk. (See <a class="local">'Variceal bleeding'</a> above and  <a class="medical medical_review" href="/d/html/1254.html" rel="external">"Overview of the management of patients with variceal bleeding"</a> and  <a class="medical medical_review" href="/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Invasive procedures</strong> – For patients undergoing invasive procedures, we optimize comorbidities such as kidney function, reduce vascular engorgement of the collateral bed (by limiting volume expansion), and treat comorbidities such as infections. We monitor the platelet count and rely on global measures of clot formation if available (or fibrinogen and platelet count if not). We do not routinely transfuse plasma for an increased prothrombin time and international normalized ratio (PT/INR) prior to a procedure. (See <a class="local">'General approach to invasive procedures'</a> above.)</p><p></p><p class="bulletIndent1">For individuals with severe thrombocytopenia (platelet count &lt;50,000/microL) who require an invasive procedure in which bleeding risk is considered to be high and for whom there is sufficient time to document an increased platelet count (eg, 10 to 13 days), we suggest considering use of a thrombopoietin receptor agonist (TPO-RA) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). <a class="drug drug_general" data-topicid="117929" href="/d/drug information/117929.html" rel="external">Avatrombopag</a> is approved in the United States and <a class="drug drug_general" data-topicid="118602" href="/d/drug information/118602.html" rel="external">lusutrombopag</a> is approved in the United States and Japan for this indication. Data support the efficacy of TPO-RAs efficacy in raising platelet counts, but these agents have not been demonstrated to reduce bleeding risk when given before procedures. Therefore, clinicians may reasonably choose close observation for procedures with a plan for rescue therapy should bleeding occur. Advice for specific procedures is presented above. (See <a class="local">'Non-surgical invasive procedures'</a> above and <a class="local">'Major surgery'</a> above.)</p><p></p><p class="bulletIndent1">For urgent or emergency procedures requiring an increase in platelet count, platelet transfusions are used. When platelets are administered, they should be given as closely as possible to the start of the procedure. (See  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Portal vein</strong> <strong>thrombosis</strong> – The clinical significance of portal vein thrombosis (PVT) continues to be debated. Prevention of PVT in individuals with liver disease focuses on optimizing hepatic function and reducing portal venous pressure. Further study is needed to clarify the role of prophylactic anticoagulation in this setting (without evident thrombus), and we do not routinely use it outside of clinical research. Treatment of PVT is discussed in detail in separate topic reviews. (See <a class="local">'Portal vein thrombosis (PVT)'</a> above and  <a class="medical medical_review" href="/d/html/3579.html" rel="external">"Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/d/html/88014.html" rel="external">"Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other sites of thrombosis</strong> – There is a paucity of data regarding other sites of venous thromboembolism (VTE) (eg, deep vein thrombosis [DVT], pulmonary embolism [PE]) risks, prevention, and treatment in patients with severe liver disease. VTE prophylaxis is appropriate for the majority of hospitalized medical and surgical patients with liver disease, similar to individuals hospitalized with other acute conditions. Therapy for VTE may be complicated by concerns about bleeding, difficulty monitoring the degree of anticoagulation, and lack of evidence to support a specific anticoagulant, dose, or duration of therapy. Dosing of anticoagulants in liver disease is summarized in the table  (<a class="graphic graphic_table graphicRef117823" href="/d/graphic/117823.html" rel="external">table 1</a>). We individualize anticoagulant therapy in collaboration between hepatologists and hematologists. (See <a class="local">'Venous thromboembolism (VTE)'</a> above and  <a class="medical medical_review" href="/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a> and  <a class="medical medical_review" href="/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p></p><p class="headingAnchor" id="H84674188"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Patrick G Northup, MD, MHES, and Stephen H Caldwell, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365:147.</a></li><li><a class="nounderline abstract_t">Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 73:366.</a></li><li><a class="nounderline abstract_t">Northup PG, Caldwell SH. Coagulation in liver disease: a guide for the clinician. Clin Gastroenterol Hepatol 2013; 11:1064.</a></li><li><a class="nounderline abstract_t">Yates SG, Gavva C, Agrawal D, Sarode R. How do we transfuse blood components in cirrhotic patients undergoing gastrointestinal procedures? Transfusion 2016; 56:791.</a></li><li><a class="nounderline abstract_t">Intagliata NM, Argo CK, Stine JG, et al. Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost 2018; 118:1491.</a></li><li><a class="nounderline abstract_t">Kalambokis GN, Oikonomou A, Christou L, et al. von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia. J Hepatol 2016; 65:921.</a></li><li><a class="nounderline abstract_t">Fisher C, Patel VC, Stoy SH, et al. Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure. J Crit Care 2018; 43:54.</a></li><li><a class="nounderline abstract_t">Blasi A, Calvo A, Prado V, et al. Coagulation Failure in Patients With Acute-on-Chronic Liver Failure and Decompensated Cirrhosis: Beyond the International Normalized Ratio. Hepatology 2018; 68:2325.</a></li><li><a class="nounderline abstract_t">Premkumar M, Saxena P, Rangegowda D, et al. Coagulation failure is associated with bleeding events and clinical outcome during systemic inflammatory response and sepsis in acute-on-chronic liver failure: An observational cohort study. Liver Int 2019; 39:694.</a></li><li><a class="nounderline abstract_t">Blasi A, Patel VC, Adelmeijer J, et al. Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acute-on-Chronic Liver Failure with Hypofibrinolysis in Those With Complications and Poor Survival. Hepatology 2020; 71:1381.</a></li><li><a class="nounderline abstract_t">Marks PW. Hematologic manifestations of liver disease. Semin Hematol 2013; 50:216.</a></li><li><a class="nounderline abstract_t">Wölpl A, Lattke H, Board PG, et al. Coagulation factor XIII A and B subunits in bone marrow and liver transplantation. Transplantation 1987; 43:151.</a></li><li><a class="nounderline abstract_t">Shah NL, Intagliata NM, Northup PG, et al. Procoagulant therapeutics in liver disease: a critique and clinical rationale. Nat Rev Gastroenterol Hepatol 2014; 11:675.</a></li><li><a class="nounderline abstract_t">Hugenholtz GC, Macrae F, Adelmeijer J, et al. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. J Thromb Haemost 2016; 14:1054.</a></li><li><a class="nounderline abstract_t">Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008; 48:1000.</a></li><li><a class="nounderline abstract_t">Qamar AA, Grace ND, Groszmann RJ, et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol 2009; 7:689.</a></li><li><a class="nounderline abstract_t">Zanetto A, Rinder HM, Campello E, et al. Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo-coagulable and Hyper-coagulable Features. Hepatology 2020; 72:1327.</a></li><li><a class="nounderline abstract_t">Bernard B, Grangé JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29:1655.</a></li><li><a class="nounderline abstract_t">Senzolo M, Coppell J, Cholongitas E, et al. The effects of glycosaminoglycans on coagulation: a thromboelastographic study. Blood Coagul Fibrinolysis 2007; 18:227.</a></li><li><a class="nounderline abstract_t">McKee RF, Hodson S, Dawes J, et al. Plasma concentrations of endogenous heparinoids in portal hypertension. Gut 1992; 33:1549.</a></li><li><a class="nounderline abstract_t">Kujovich JL. Hemostatic defects in end stage liver disease. Crit Care Clin 2005; 21:563.</a></li><li><a class="nounderline abstract_t">Ferro D, Celestini A, Violi F. Hyperfibrinolysis in liver disease. Clin Liver Dis 2009; 13:21.</a></li><li><a class="nounderline abstract_t">Bennani-Baiti N, Daw HA. Primary hyperfibrinolysis in liver disease: a critical review. Clin Adv Hematol Oncol 2011; 9:250.</a></li><li><a class="nounderline abstract_t">Nair GB, Lajin M, Muslimani A. A cirrhotic patient with spontaneous intramuscular hematoma due to primary hyperfibrinolysis. Clin Adv Hematol Oncol 2011; 9:249.</a></li><li><a class="nounderline abstract_t">Nicolau-Raducu R, Beduschi T, Vianna R, et al. Fibrinolysis Shutdown Is Associated With Thrombotic and Hemorrhagic Complications and Poorer Outcomes After Liver Transplantation. Liver Transpl 2019; 25:380.</a></li><li><a class="nounderline abstract_t">Seested T, Appa RS, Christensen EI, et al. In vivo clearance and metabolism of recombinant activated factor VII (rFVIIa) and its complexes with plasma protease inhibitors in the liver. Thromb Res 2011; 127:356.</a></li><li><a class="nounderline abstract_t">Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001; 85:667.</a></li><li><a class="nounderline abstract_t">Bedreli S, Sowa JP, Malek S, et al. Rotational thromboelastometry can detect factor XIII deficiency and bleeding diathesis in patients with cirrhosis. Liver Int 2017; 37:562.</a></li><li><a class="nounderline abstract_t">Agarwal S, Joyner KA Jr, Swaim MW. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease. Am J Gastroenterol 2000; 95:3218.</a></li><li><a class="nounderline abstract_t">Sinegre T, Duron C, Lecompte T, et al. Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis. J Thromb Haemost 2018; 16:1132.</a></li><li><a class="nounderline abstract_t">Lisman T, Bos S, Intagliata NM. Mechanisms of enhanced thrombin-generating capacity in patients with cirrhosis. J Thromb Haemost 2018; 16:1128.</a></li><li><a class="nounderline abstract_t">Elvers FL, Stamouli M, Adelmeijer J, et al. In vivo generation of thrombin in patients with liver disease without apparent evidence of activation of the intrinsic or extrinsic pathway of coagulation. J Thromb Haemost 2023; 21:2078.</a></li><li><a class="nounderline abstract_t">Schmaier AH. Coagulopathy of liver disease-a pathophysiologic rebalance of hemostasis and thrombosis. J Thromb Haemost 2023; 21:2045.</a></li><li><a class="nounderline abstract_t">Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44:53.</a></li><li><a class="nounderline abstract_t">Palyu E, Harsfalvi J, Tornai T, et al. Major Changes of von Willebrand Factor Multimer Distribution in Cirrhotic Patients with Stable Disease or Acute Decompensation. Thromb Haemost 2018; 118:1397.</a></li><li><a class="nounderline abstract_t">Pereboom IT, Adelmeijer J, van Leeuwen Y, et al. Development of a severe von Willebrand factor/ADAMTS13 dysbalance during orthotopic liver transplantation. Am J Transplant 2009; 9:1189.</a></li><li><a class="nounderline abstract_t">Ferro D, Quintarelli C, Lattuada A, et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996; 23:1377.</a></li><li><a class="nounderline abstract_t">Bos S, van den Boom B, Kamphuisen PW, et al. Haemostatic Profiles are Similar across All Aetiologies of Cirrhosis. Thromb Haemost 2019; 119:246.</a></li><li><a class="nounderline abstract_t">Weeder PD, Porte RJ, Lisman T. Hemostasis in liver disease: implications of new concepts for perioperative management. Transfus Med Rev 2014; 28:107.</a></li><li><a class="nounderline abstract_t">Witters P, Freson K, Verslype C, et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther 2008; 27:1017.</a></li><li><a class="nounderline abstract_t">Ben-Ari Z, Panagou M, Patch D, et al. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J Hepatol 1997; 26:554.</a></li><li><a class="nounderline abstract_t">Pihusch R, Rank A, Göhring P, et al. Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatol 2002; 37:548.</a></li><li><a class="nounderline abstract_t">Stine JG, Shah NL, Argo CK, et al. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. Liver Transpl 2015; 21:1016.</a></li><li><a class="nounderline abstract_t">Potze W, Siddiqui MS, Boyett SL, et al. Preserved hemostatic status in patients with non-alcoholic fatty liver disease. J Hepatol 2016; 65:980.</a></li><li><a class="nounderline abstract_t">Stine JG, Niccum BA, Zimmet AN, et al. Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis. Clin Transl Gastroenterol 2018; 9:140.</a></li><li><a class="nounderline abstract_t">Lisman T, Kleiss S, Patel VC, et al. In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis. Liver Int 2018; 38:1988.</a></li><li><a class="nounderline abstract_t">Intagliata NM, Davis JPE, Caldwell SH. Coagulation Pathways, Hemostasis, and Thrombosis in Liver Failure. Semin Respir Crit Care Med 2018; 39:598.</a></li><li><a class="nounderline abstract_t">Stravitz RT, Lisman T, Luketic VA, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2012; 56:129.</a></li><li><a class="nounderline abstract_t">Stravitz RT, Ellerbe C, Durkalski V, et al. Bleeding complications in acute liver failure. Hepatology 2018; 67:1931.</a></li><li><a class="nounderline abstract_t">Giannini EG, Giambruno E, Brunacci M, et al. Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients. Ann Hepatol 2018; 17:830.</a></li><li><a class="nounderline abstract_t">Budnick IM, Davis JPE, Sundararaghavan A, et al. Transfusion with Cryoprecipitate for Very Low Fibrinogen Levels Does Not Affect Bleeding or Survival in Critically Ill Cirrhosis Patients. Thromb Haemost 2021; 121:1317.</a></li><li><a class="nounderline abstract_t">Davis JPE, Northup PG, Caldwell SH, Intagliata NM. Viscoelastic Testing in Liver Disease. Ann Hepatol 2018; 17:205.</a></li><li><a class="nounderline abstract_t">Lisman T. Interpreting Hemostatic Profiles Assessed With Viscoelastic Tests in Patients With Cirrhosis. J Clin Gastroenterol 2020; 54:389.</a></li><li><a class="nounderline abstract_t">Stravitz RT, Fontana RJ, Meinzer C, et al. Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure. Hepatology 2021; 74:937.</a></li><li><a class="nounderline abstract_t">De Pietri L, Bianchini M, Montalti R, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology 2016; 63:566.</a></li><li><a class="nounderline abstract_t">Rocha LL, Neto AS, Pessoa CMS, et al. Comparison of three transfusion protocols prior to central venous catheterization in patients with cirrhosis: A randomized controlled trial. J Thromb Haemost 2020; 18:560.</a></li><li><a class="nounderline abstract_t">Vuyyuru SK, Singh AD, Gamanagatti SR, et al. A Randomized Control Trial of Thromboelastography-Guided Transfusion in Cirrhosis for High-Risk Invasive Liver-Related Procedures. Dig Dis Sci 2020; 65:2104.</a></li><li><a class="nounderline abstract_t">Northup P, Davis J. Shortcomings in Design and Analysis of Clinical Studies on Bleeding and Thrombosis in Patients with Cirrhosis. Semin Thromb Hemost 2020; 46:665.</a></li><li><a class="nounderline abstract_t">Shamseddeen H, Patidar KR, Ghabril M, et al. Features of Blood Clotting on Thromboelastography in Hospitalized Patients With Cirrhosis. Am J Med 2020; 133:1479.</a></li><li><a class="nounderline abstract_t">Hum J, Amador D, Shatzel JJ, et al. Thromboelastography Better Reflects Hemostatic Abnormalities in Cirrhotics Compared With the International Normalized Ratio. J Clin Gastroenterol 2020; 54:741.</a></li><li><a class="nounderline abstract_t">Tripodi A, Primignani M, Chantarangkul V, et al. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res 2009; 124:132.</a></li><li><a class="nounderline abstract_t">Kohli R, Shingina A, New S, et al. Thromboelastography Parameters Are Associated with Cirrhosis Severity. Dig Dis Sci 2019; 64:2661.</a></li><li><a class="nounderline abstract_t">Mallett SV, Chowdary P, Burroughs AK. Clinical utility of viscoelastic tests of coagulation in patients with liver disease. Liver Int 2013; 33:961.</a></li><li><a class="nounderline abstract_t">Nanchal R, Subramanian R, Karvellas CJ, et al. Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Cardiovascular, Endocrine, Hematologic, Pulmonary, and Renal Considerations. Crit Care Med 2020; 48:e173.</a></li><li><a class="nounderline abstract_t">O'Shea RS, Davitkov P, Ko CW, et al. AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis. Gastroenterology 2021; 161:1615.</a></li><li><a class="nounderline abstract_t">Rassi AB, d'Amico EA, Tripodi A, et al. Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation. J Hepatol 2020; 72:85.</a></li><li><a class="nounderline abstract_t">Carnevale R, Raparelli V, Nocella C, et al. Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis. J Hepatol 2017; 67:950.</a></li><li><a class="nounderline abstract_t">Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2018; 2:3198.</a></li><li><a class="nounderline abstract_t">Mort JF, Davis JPE, Mahoro G, et al. Rates of Bleeding and Discontinuation of Direct Oral Anticoagulants in Patients With Decompensated Cirrhosis. Clin Gastroenterol Hepatol 2021; 19:1436.</a></li><li><a class="nounderline abstract_t">Bos S, Schreuder T, Blokzijl H, et al. Anticoagulant activity of edoxaban in patients with cirrhosis. Blood 2020; 136:1561.</a></li><li><a class="nounderline abstract_t">Potze W, Adelmeijer J, Lisman T. Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis. Hepatology 2015; 61:1435.</a></li><li><a class="nounderline abstract_t">Potze W, Arshad F, Adelmeijer J, et al. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. PLoS One 2014; 9:e88390.</a></li><li><a class="nounderline abstract_t">Intagliata NM, Maitland H, Pellitier S, Caldwell SH. Reversal of direct oral anticoagulants for liver transplantation in cirrhosis: A step forward. Liver Transpl 2017; 23:396.</a></li><li><a class="nounderline abstract_t">Bechmann LP, Sichau M, Wichert M, et al. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011; 31:75.</a></li><li><a class="nounderline abstract_t">Fuentes A, Gordon-Burroughs S, Hall JB, et al. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis. Ther Drug Monit 2015; 37:40.</a></li><li><a class="nounderline abstract_t">Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. N Engl J Med 2001; 345:669.</a></li><li><a class="nounderline abstract_t">Shah NL, Northup PG, Caldwell SH. A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients. Ann Hepatol 2012; 11:686.</a></li><li><a class="nounderline abstract_t">Campello E, Zanetto A, Radu CM, et al. Acute kidney injury is associated with increased levels of circulating microvesicles in patients with decompensated cirrhosis. Dig Liver Dis 2021; 53:879.</a></li><li><a class="nounderline abstract_t">Intagliata NM, Davis JPE, Lafond J, et al. Acute kidney injury is associated with low factor XIII in decompensated cirrhosis. Dig Liver Dis 2019; 51:1409.</a></li><li><a class="nounderline abstract_t">Kumar M, Ahmad J, Maiwall R, et al. Thromboelastography-Guided Blood Component Use in Patients With Cirrhosis With Nonvariceal Bleeding: A Randomized Controlled Trial. Hepatology 2020; 71:235.</a></li><li><a class="nounderline abstract_t">Rout G, Shalimar, Gunjan D, et al. Thromboelastography-guided Blood Product Transfusion in Cirrhosis Patients With Variceal Bleeding: A Randomized Controlled Trial. J Clin Gastroenterol 2020; 54:255.</a></li><li><a class="nounderline abstract_t">Britt RB, Brown JN. Characterizing the Severe Reactions of Parenteral Vitamin K1. Clin Appl Thromb Hemost 2018; 24:5.</a></li><li><a class="nounderline abstract_t">Pandit TN, Sarode R. Blood component support in acquired coagulopathic conditions: is there a method to the madness? Am J Hematol 2012; 87 Suppl 1:S56.</a></li><li><a class="nounderline abstract_t">Tischendorf M, Fuchs A, Zeuzem S, Lange CM. Use of prothrombin complex concentrates in patients with decompensated liver cirrhosis is associated with thromboembolic events. J Hepatol 2019; 70:800.</a></li><li><a class="nounderline abstract_t">Glass JP, Im GY. DIC in decompensated cirrhosis caused by prothrombin complex concentrate and recombinant activated factor VII: A word of caution. Liver Int 2017; 37:1412.</a></li><li><a class="nounderline abstract_t">Groeneveld DJ, Adelmeijer J, Hugenholtz GC, et al. Ex vivo addition of fibrinogen concentrate improves the fibrin network structure in plasma samples taken during liver transplantation. J Thromb Haemost 2015; 13:2192.</a></li><li><a class="nounderline abstract_t">Kirchner C, Dirkmann D, Treckmann JW, et al. Coagulation management with factor concentrates in liver transplantation: a single-center experience. Transfusion 2014; 54:2760.</a></li><li><a class="nounderline abstract_t">Lim HI, Cuker A. Thrombocytopenia and liver disease: pathophysiology and periprocedural management. Hematology Am Soc Hematol Educ Program 2022; 2022:296.</a></li><li><a class="nounderline abstract_t">Leebeek FW, Rijken DC. The Fibrinolytic Status in Liver Diseases. Semin Thromb Hemost 2015; 41:474.</a></li><li><a class="nounderline abstract_t">ALBRECHTSEN OK, STORM O, CLAASSEN M. Fibrinolytic activity in some human body fluids. Scand J Clin Lab Invest 1958; 10:310.</a></li><li><a class="nounderline abstract_t">HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet 2020; 395:1927.</a></li><li><a class="nounderline abstract_t">Sasso R, Rockey DC. Anticoagulation Therapy in Patients with Liver Cirrhosis is Associated With an Increased Risk of Variceal Hemorrhage. Am J Med 2019; 132:758.</a></li><li><a class="nounderline abstract_t">Cerini F, Gonzalez JM, Torres F, et al. Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. Hepatology 2015; 62:575.</a></li><li><a class="nounderline abstract_t">Bianchini M, Cavani G, Bonaccorso A, et al. Low molecular weight heparin does not increase bleeding and mortality post-endoscopic variceal band ligation in cirrhotic patients. Liver Int 2018; 38:1253.</a></li><li><a class="nounderline abstract_t">Intagliata NM, Rahimi RS, Higuera-de-la-Tijera F, et al. Procedural-Related Bleeding in Hospitalized Patients With Liver Disease (PROC-BLeeD): An International, Prospective, Multicenter Observational Study. Gastroenterology 2023; 165:717.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. Electronic address: <span class="__cf_email__" data-cfemail="a3c6c2d0cfccc5c5cac0c6e3c6c2d0cfccc5c5cac0c68dc6d6">[email protected]</span>, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol 2022; 76:1151.</a></li><li><a class="nounderline abstract_t">Intagliata NM, Caldwell SH, Porte RJ, Lisman T. Prediction of bleeding in cirrhosis patients: Is the forecast any clearer? Hepatology 2016; 64:989.</a></li><li><a class="nounderline abstract_t">Zanetto A, Rinder HM, Senzolo M, et al. Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedure‐Related Bleeding in Decompensated Cirrhosis. Hepatol Commun 2020.</a></li><li class="breakAll">https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep4.1641 (Accessed on February 05, 2021).</li><li><a class="nounderline abstract_t">Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44:440.</a></li><li><a class="nounderline abstract_t">Giannini EG, Greco A, Marenco S, et al. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol 2010; 8:899.</a></li><li><a class="nounderline abstract_t">Napolitano G, Iacobellis A, Merla A, et al. Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia. Eur J Intern Med 2017; 38:79.</a></li><li><a class="nounderline abstract_t">Intagliata NM, Davitkov P, Allen AM, et al. AGA Technical Review on Coagulation in Cirrhosis. Gastroenterology 2021; 161:1630.</a></li><li><a class="nounderline abstract_t">Terrault N, Chen YC, Izumi N, et al. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. Gastroenterology 2018; 155:705.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf (Accessed on May 22, 2018).</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210923s000lbl.pdf (Accessed on July 31, 2018).</li><li><a class="nounderline abstract_t">Kim ES. Lusutrombopag: First Global Approval. Drugs 2016; 76:155.</a></li><li><a class="nounderline abstract_t">Rai R, Nagral S, Nagral A. Surgery in a patient with liver disease. J Clin Exp Hepatol 2012; 2:238.</a></li><li><a class="nounderline abstract_t">Stellingwerff M, Brandsma A, Lisman T, Porte RJ. Prohemostatic interventions in liver surgery. Semin Thromb Hemost 2012; 38:244.</a></li><li><a class="nounderline abstract_t">Kor DJ, Stubbs JR, Gajic O. Perioperative coagulation management--fresh frozen plasma. Best Pract Res Clin Anaesthesiol 2010; 24:51.</a></li><li><a class="nounderline abstract_t">Ng VL. Liver disease, coagulation testing, and hemostasis. Clin Lab Med 2009; 29:265.</a></li><li class="breakAll">http://www.aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf (Accessed on July 15, 2015).</li><li><a class="nounderline abstract_t">Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49:2087.</a></li><li><a class="nounderline abstract_t">Hung A, Garcia-Tsao G. Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in patients with decompensated cirrhosis. Liver Int 2018; 38:1437.</a></li><li><a class="nounderline abstract_t">Patel IJ, Rahim S, Davidson JC, et al. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part II: Recommendations: Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol 2019; 30:1168.</a></li><li><a class="nounderline abstract_t">Hibbert RM, Atwell TD, Lekah A, et al. Safety of ultrasound-guided thoracentesis in patients with abnormal preprocedural coagulation parameters. Chest 2013; 144:456.</a></li><li><a class="nounderline abstract_t">Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981; 26:388.</a></li><li><a class="nounderline abstract_t">Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009; 49:1017.</a></li><li><a class="nounderline abstract_t">Medina JB, Andrade NS, de Paula Eduardo F, et al. Bleeding during and after dental extractions in patients with liver cirrhosis. Int J Oral Maxillofac Surg 2018; 47:1543.</a></li><li><a class="nounderline abstract_t">Pereira Tdos S, Pelinsari FC, Ruas BM, et al. Postoperative complications after dental extraction in liver pretransplant patients. Spec Care Dentist 2016; 36:277.</a></li><li><a class="nounderline abstract_t">Stanca CM, Montazem AH, Lawal A, et al. Intranasal desmopressin versus blood transfusion in cirrhotic patients with coagulopathy undergoing dental extraction: a randomized controlled trial. J Oral Maxillofac Surg 2010; 68:138.</a></li><li><a class="nounderline abstract_t">Villa E, Cammà C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143:1253.</a></li><li><a class="nounderline abstract_t">Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology 2015; 61:660.</a></li><li><a class="nounderline abstract_t">Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. Gastroenterology 2019; 156:1582.</a></li><li><a class="nounderline abstract_t">Intagliata NM, Saad WE, Caldwell SH. Effects of restoring portal flow with anticoagulation and partial splenorenal shunt embolization. Hepatology 2015; 61:1088.</a></li><li><a class="nounderline abstract_t">Buresi M, Hull R, Coffin CS. Venous thromboembolism in cirrhosis: a review of the literature. Can J Gastroenterol 2012; 26:905.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. Electronic address: <span class="__cf_email__" data-cfemail="9bfefae8f7f4fdfdf2f8fedbfefae8f7f4fdfdf2f8feb5feee">[email protected]</span>. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016; 64:179.</a></li><li><a class="nounderline abstract_t">Fontana RJ. Prophylactic anticoagulation in cirrhotics: a paradox for prime time? Gastroenterology 2012; 143:1138.</a></li><li><a class="nounderline abstract_t">Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol 2014; 11:435.</a></li><li class="breakAll">https://clinicaltrials.gov/ct2/show/NCT02643212 (Accessed on March 28, 2019).</li><li><a class="nounderline abstract_t">Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. Gastroenterology 2017; 153:480.</a></li><li><a class="nounderline abstract_t">Søgaard KK, Horváth-Puhó E, Montomoli J, et al. Cirrhosis is Associated with an Increased 30-Day Mortality After Venous Thromboembolism. Clin Transl Gastroenterol 2015; 6:e97.</a></li><li><a class="nounderline abstract_t">Roberts LN, Hernandez-Gea V, Magnusson M, et al. Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: Guidance from the SSC of the ISTH. J Thromb Haemost 2022; 20:2237.</a></li><li><a class="nounderline abstract_t">Bikdeli B, Jiménez D, Garcia-Tsao G, et al. Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro Informatizado de la Enfermedad TromboEmbolica) Registry. Semin Thromb Hemost 2019; 45:793.</a></li><li><a class="nounderline abstract_t">Qi X, Ren W, Guo X, Fan D. Epidemiology of venous thromboembolism in patients with liver diseases: a systematic review and meta-analysis. Intern Emerg Med 2015; 10:205.</a></li><li><a class="nounderline abstract_t">Ambrosino P, Tarantino L, Criscuolo L, et al. The risk of venous thromboembolism in patients with hepatitis C. A systematic review and meta-analysis. Thromb Haemost 2016; 116:958.</a></li><li><a class="nounderline abstract_t">Saleh T, Matta F, Alali F, Stein PD. Venous thromboembolism with chronic liver disease. Am J Med 2011; 124:64.</a></li><li><a class="nounderline abstract_t">Ambrosino P, Tarantino L, Di Minno G, et al. The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost 2017; 117:139.</a></li><li><a class="nounderline abstract_t">Ali M, Ananthakrishnan AN, McGinley EL, Saeian K. Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis. Dig Dis Sci 2011; 56:2152.</a></li><li><a class="nounderline abstract_t">Ng KJ, Lee YK, Huang MY, et al. Risks of venous thromboembolism in patients with liver cirrhosis: a nationwide cohort study in Taiwan. J Thromb Haemost 2015; 13:206.</a></li><li><a class="nounderline abstract_t">Bogari H, Patanwala AE, Cosgrove R, Katz M. Risk-assessment and pharmacological prophylaxis of venous thromboembolism in hospitalized patients with chronic liver disease. Thromb Res 2014; 134:1220.</a></li><li><a class="nounderline abstract_t">Davis JPE, O'Leary KE, Intagliata NM. Overuse of venous thromboembolism prophylaxis among hospitalized patients with liver disease. Eur J Haematol 2020; 104:223.</a></li><li><a class="nounderline abstract_t">Intagliata NM, Henry ZH, Shah N, et al. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int 2014; 34:26.</a></li><li><a class="nounderline abstract_t">Shatzel J, Dulai PS, Harbin D, et al. Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single-center retrospective cohort study. J Thromb Haemost 2015; 13:1245.</a></li><li><a class="nounderline abstract_t">Intagliata NM, Maitland H, Northup PG, Caldwell SH. Treating thrombosis in cirrhosis patients with new oral agents: ready or not? Hepatology 2015; 61:738.</a></li><li><a class="nounderline abstract_t">Intagliata NM, Henry ZH, Maitland H, et al. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Dig Dis Sci 2016; 61:1721.</a></li><li><a class="nounderline abstract_t">Hum J, Shatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol 2017; 98:393.</a></li><li><a class="nounderline abstract_t">Lisman T, Porte RJ. Towards a rational use of low-molecular-weight heparin in patients with cirrhosis. Liver Int 2011; 31:1063.</a></li><li><a class="nounderline abstract_t">Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54:691.</a></li><li><a class="nounderline abstract_t">Amitrano L, Guardascione MA, Menchise A, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010; 44:448.</a></li><li><a class="nounderline abstract_t">Condat B, Pessione F, Helene Denninger M, et al. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32:466.</a></li><li><a class="nounderline abstract_t">La Mura V, Braham S, Tosetti G, et al. Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis. Clin Gastroenterol Hepatol 2018; 16:1146.</a></li><li><a class="nounderline abstract_t">Lisman T, Bakhtiari K, Adelmeijer J, et al. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. J Thromb Haemost 2012; 10:1312.</a></li><li><a class="nounderline abstract_t">Munoz SJ, Rajender Reddy K, Lee W, Acute Liver Failure Study Group. The coagulopathy of acute liver failure and implications for intracranial pressure monitoring. Neurocrit Care 2008; 9:103.</a></li></ol></div><div id="topicVersionRevision">Topic 13932 Version 68.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21751907" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The coagulopathy of chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33219529" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23506859" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Coagulation in liver disease: a guide for the clinician.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26876945" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : How do we transfuse blood components in cirrhotic patients undergoing gastrointestinal procedures?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30060258" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27297911" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28843665" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29790188" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Coagulation Failure in Patients With Acute-on-Chronic Liver Failure and Decompensated Cirrhosis: Beyond the International Normalized Ratio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30589495" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Coagulation failure is associated with bleeding events and clinical outcome during systemic inflammatory response and sepsis in acute-on-chronic liver failure: An observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31465557" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acute-on-Chronic Liver Failure with Hypofibrinolysis in Those With Complications and Poor Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23953338" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hematologic manifestations of liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3541316" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Coagulation factor XIII A and B subunits in bone marrow and liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25023035" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Procoagulant therapeutics in liver disease: a critique and clinical rationale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26833718" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18433919" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Thrombocytopenia associated with chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19281860" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32614088" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo-coagulable and Hyper-coagulable Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10347104" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17413758" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The effects of glycosaminoglycans on coagulation: a thromboelastographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1452082" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Plasma concentrations of endogenous heparinoids in portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15992673" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hemostatic defects in end stage liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19150306" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hyperfibrinolysis in liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21475135" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Primary hyperfibrinolysis in liver disease: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21475134" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A cirrhotic patient with spontaneous intramuscular hematoma due to primary hyperfibrinolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30548128" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Fibrinolysis Shutdown Is Associated With Thrombotic and Hemorrhagic Complications and Poorer Outcomes After Liver Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21262526" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : In vivo clearance and metabolism of recombinant activated factor VII (rFVIIa) and its complexes with plasma protease inhibitors in the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11341503" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27634287" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Rotational thromboelastometry can detect factor XIII deficiency and bleeding diathesis in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095345" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29577605" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29633495" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mechanisms of enhanced thrombin-generating capacity in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36990155" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : In vivo generation of thrombin in patients with liver disease without apparent evidence of activation of the intrinsic or extrinsic pathway of coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37468173" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Coagulopathy of liver disease-a pathophysiologic rebalance of hemostasis and thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16799972" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29972862" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Major Changes of von Willebrand Factor Multimer Distribution in Cirrhotic Patients with Stable Disease or Acute Decompensation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19422343" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Development of a severe von Willebrand factor/ADAMTS13 dysbalance during orthotopic liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8675154" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30609442" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Haemostatic Profiles are Similar across All Aetiologies of Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24721432" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hemostasis in liver disease: implications of new concepts for perioperative management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18331464" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Review article: blood platelet number and function in chronic liver disease and cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9075662" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12399218" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25845711" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27302378" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Preserved hemostatic status in patients with non-alcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29511162" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29768734" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30485890" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Coagulation Pathways, Hemostasis, and Thrombosis in Liver Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21703173" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29194678" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Bleeding complications in acute liver failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30145561" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33450778" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Transfusion with Cryoprecipitate for Very Low Fibrinogen Levels Does Not Affect Bleeding or Survival in Critically Ill Cirrhosis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29469043" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Viscoelastic Testing in Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32028285" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Interpreting Hemostatic Profiles Assessed With Viscoelastic Tests in Patients With Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33636020" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26340411" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31667992" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparison of three transfusion protocols prior to central venous catheterization in patients with cirrhosis: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31720889" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A Randomized Control Trial of Thromboelastography-Guided Transfusion in Cirrhosis for High-Risk Invasive Liver-Related Procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32757183" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Shortcomings in Design and Analysis of Clinical Studies on Bleeding and Thrombosis in Patients with Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32473871" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Features of Blood Clotting on Thromboelastography in Hospitalized Patients With Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31764489" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Thromboelastography Better Reflects Hemostatic Abnormalities in Cirrhotics Compared With the International Normalized Ratio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19135704" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30915655" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Thromboelastography Parameters Are Associated with Cirrhosis Severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23638693" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical utility of viscoelastic tests of coagulation in patients with liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32058387" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Cardiovascular, Endocrine, Hematologic, Pulmonary, and Renal Considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34579936" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31536747" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28716745" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30482763" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32777555" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Rates of Bleeding and Discontinuation of Direct Oral Anticoagulants in Patients With Decompensated Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32458002" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Anticoagulant activity of edoxaban in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25088782" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24505487" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28026110" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Reversal of direct oral anticoagulants for liver transplantation in cirrhosis: A step forward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20958919" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Low-molecular-weight heparin in patients with advanced cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24901494" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11547722" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Gastroesophageal variceal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22947530" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 :  A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33431230" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Acute kidney injury is associated with increased levels of circulating microvesicles in patients with decompensated cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30967339" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Acute kidney injury is associated with low factor XIII in decompensated cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31148204" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Thromboelastography-Guided Blood Component Use in Patients With Cirrhosis With Nonvariceal Bleeding: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31008867" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Thromboelastography-guided Blood Product Transfusion in Cirrhosis Patients With Variceal Bleeding: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28301903" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Characterizing the Severe Reactions of Parenteral Vitamin K1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473878" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Blood component support in acquired coagulopathic conditions: is there a method to the madness?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30630599" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Use of prothrombin complex concentrates in patients with decompensated liver cirrhosis is associated with thromboembolic events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28609569" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : DIC in decompensated cirrhosis caused by prothrombin complex concentrate and recombinant activated factor VII: A word of caution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26453059" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Ex vivo addition of fibrinogen concentrate improves the fibrin network structure in plasma samples taken during liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24827116" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Coagulation management with factor concentrates in liver transplantation: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36485111" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Thrombocytopenia and liver disease: pathophysiology and periprocedural management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26049070" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The Fibrinolytic Status in Liver Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13602704" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Fibrinolytic activity in some human body fluids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32563378" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30660572" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Anticoagulation Therapy in Patients with Liver Cirrhosis is Associated With an Increased Risk of Variceal Hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25773591" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29469184" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Low molecular weight heparin does not increase bleeding and mortality post-endoscopic variceal band ligation in cirrhotic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37271290" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Procedural-Related Bleeding in Hospitalized Patients With Liver Disease (PROC-BLeeD): An International, Prospective, Multicenter Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35300861" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26704886" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Prediction of bleeding in cirrhosis patients: Is the forecast any clearer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedure‐Related Bleeding in Decompensated Cirrhosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedure‐Related Bleeding in Decompensated Cirrhosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16871542" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Thrombin generation in patients with cirrhosis: the role of platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20601131" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27989373" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34579937" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : AGA Technical Review on Coagulation in Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29778606" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29778606" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29778606" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26666417" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Lusutrombopag: First Global Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25755440" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Surgery in a patient with liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22510858" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Prohemostatic interventions in liver surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20402170" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Perioperative coagulation management--fresh frozen plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19665678" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Liver disease, coagulation testing, and hemostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19665678" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Liver disease, coagulation testing, and hemostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19475696" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Management of adult patients with ascites due to cirrhosis: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29393567" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in patients with decompensated cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31229333" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part II: Recommendations: Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23493971" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Safety of ultrasound-guided thoracentesis in patients with abnormal preprocedural coagulation parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7249879" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Bleeding after liver biopsy does not correlate with indices of peripheral coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19243014" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Liver biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29705406" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Bleeding during and after dental extractions in patients with liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27061180" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Postoperative complications after dental extraction in liver pretransplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20006168" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Intranasal desmopressin versus blood transfusion in cirrhotic patients with coagulopathy undergoing dental extraction: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22819864" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25284616" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30771355" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24867875" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Effects of restoring portal flow with anticoagulation and partial splenorenal shunt embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23248793" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Venous thromboembolism in cirrhosis: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26516032" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : EASL Clinical Practice Guidelines: Vascular diseases of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23000228" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Prophylactic anticoagulation in cirrhotics: a paradox for prime time?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24686266" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Management of portal vein thrombosis in liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24686266" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Management of portal vein thrombosis in liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28479379" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26133110" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Cirrhosis is Associated with an Increased 30-Day Mortality After Venous Thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35948998" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: Guidance from the SSC of the ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31614388" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro Informatizado de la Enfermedad TromboEmbolica) Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25472621" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Epidemiology of venous thromboembolism in patients with liver diseases: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27411407" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : The risk of venous thromboembolism in patients with hepatitis C. A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21187186" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Venous thromboembolism with chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27761574" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21279685" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25471737" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Risks of venous thromboembolism in patients with liver cirrhosis: a nationwide cohort study in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25294587" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Risk-assessment and pharmacological prophylaxis of venous thromboembolism in hospitalized patients with chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31797441" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Overuse of venous thromboembolism prophylaxis among hospitalized patients with liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23758818" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25955079" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single-center retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24829112" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Treating thrombosis in cirrhosis patients with new oral agents: ready or not?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26725062" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28009449" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21733099" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Towards a rational use of low-molecular-weight heparin in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15831918" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19730112" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10960436" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29066371" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22568491" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18379899" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : The coagulopathy of acute liver failure and implications for intracranial pressure monitoring.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
